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ABSTRACT 
 
STATISTICAL METHODS AND ANALYSIS IN GENOME WIDE 
ASSOCIATION STUDIES AND NEXT-GENERATION SEQUENCING   
 
by  
 
Wei Chen 
 
  
Chair: Gonçalo R. Abecasis 
 
Genome-wide association studies (GWAS), which examine common genetic variants in 
thousands of individuals, have identified many genetic loci associated with a variety of 
complex diseases and phenotypes. New Next-Generation Sequencing (NGS) technologies 
allow us to extend these studies to rarer variants not typically evaluated by GWAS. In 
this dissertation, I present novel statistical methods and software to dissect the genetic 
basis of complex traits in the context of both GWAS and NGS.  
 
First, I present a large-scale GWAS for Age-related Macular Degeneration (AMD). Our 
studies extend the catalog of AMD associated loci and provide clues about underlying 
cellular pathways. A novelty in our study is that I propose a prediction method using all 
susceptibility loci to help identify individuals at high risk of disease. The prediction can 
be extended to the general population with a weighted scheme combining both disease 
prevalence and case-control ratio in GWAS sample.   
 
 
 
ix 
 
Second, I describe an interactive package that provides graphical overviews of the results 
of whole-genome association studies in datasets with rich multi-dimensional phenotypic 
information, such as global surveys of gene expression.  
 
Third, I propose and implement an efficient Hidden Markov Model (HMM) based 
method for genotype calling and haplotype inference in parent-offspring trios. Our 
method considers both linkage disequilibrium (LD) patterns and the constraints imposed 
by the family structure in assigning individual genotypes and haplotypes. Using 
simulations and sequencing data from ongoing projects, I show that trios provide higher 
genotype calling accuracy across the frequency spectrum, both overall and at hard-to-call 
heterozygous sites. In addition, sequencing trios can provide greatly improved haplotype 
phasing accuracy. 
 
Finally, I describe an efficient state space reduction method for haplotype inference and 
genotype calling. This method is motivated by the increasing computational challenge of 
HMM-based approaches used to describe haplotype sharing in GWAS and NGS data. 
Our method takes advantage of local similarity between haplotypes and reduces the 
HMM state space dynamically, while preserving the same accuracy of full state space 
method. Through simulation and real data analysis, I show that this method can have 
substantial savings in both memory and CPU time. 
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Chapter 1  
 
Introduction and the Scope of this Dissertation 
 
 
1.1 Genetic Study of Complex Diseases  
 
Modern genetics originated from simple Mendelian disorders back to a century ago. In 
the past decades, more attention has been paid to complex traits, which are much more 
complicated and caused by both genetic and environmental factors. To understand the 
genetic basis of complex diseases and many common phenotypes, linkage analysis and 
association analysis, have made substantial progress in the past few decades [1, 2]. Due 
to the high experimental cost and limitations of biology technology, only a small fraction 
or a few short regions of the genome were studied and thus the localization of the 
disease-associated variants was very limited. Shortly after the completion of Human 
Genome Project, genome-wide association study (GWAS) became a feasible and 
powerful approach to uncover genetic variants with much better resolution by examining 
hundreds of thousands of Single Nucleotide Polymorphisms (SNPs) across the whole 
genome. Over one thousand loci susceptible to common diseases and phenotypes have 
been revealed [3-5] and have led to subsequent functional analysis in biomedical area. 
Despite the number of loci identified, GWAS are based on the hypothesis of common 
disease / common variant (CDCV) and a large proportion of heritability has not been 
explained [6]. Rare variants are believed to play an important role in the missing 
heritability. To study rare variants and pinpoint the causal alleles more accurately, 
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sequencing technology has been advanced rapidly in the past few years, boosted by 
several worldwide giant projects such as 1000 Genomes Project (ww.1000genomes.org). 
Next-generation sequencing (NGS) allows us to detect more variants, including SNPs and 
structural variations, and explore rare variants systematically beyond common variants 
assayed by GWAS. 
 
1.2 Statistical and Computational Challenges in GWAS and NGS 
 
Compared to the genetic studies back to thirty years ago, GWAS and NGS generate a 
huge amount of data. For GWAS, thousands of samples are collected and genotyped 
using commercial or customized microarray chips examining hundreds of thousands to 
millions of variants across the genome.  Statistical methods are crucial to analyze such 
data sets [7]. A few successful examples include but are not limit to a) power calculation 
for study design; b) genotype imputation for meta-analysis and examining more variants; 
c) methods for adjusting population stratification; d) methods for adjusting multiple 
testing. For NGS, the data scale grows to another level. The statistical and computational 
challenges mainly lie on two levels: a) lower level variants calling and haplotype 
inference from sequencing data; b) upper level association tests involving rare variants 
and structural variations. Unlike very accurate genotypes from GWAS, high throughput 
sequencing machine generates millions of short fragments of the genome. This process 
requires accurate and efficient statistical algorithms for mapping and genotype calling. 
The accuracy of genotypes is critical to follow-up association studies. New association 
tests are required in the context of NGS. For example, traditional association methods 
might be underpowered if disease is caused by multiple rare variants. The successful 
imputation and haplotype inference methods in GWAS become less feasible given 
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greatly increased number of samples and DNA variants. Efficient computational methods 
and updated computer hardware are required to overcome these practical issues. 
 
1.3 The Scope of this Dissertation 
 
In this dissertation, I will present both methodologies and software developments about 
imputation, SNP calling, haplotype inference and multiple testing motivated by the 
challenges previously described; I will also present novel scientific findings on age-
related macular degeneration and visualization tools developed for efficiently storing and 
displaying GWAS results with high-dimensional phenotypes.  
 
In chapter 2, I present a genome-wide association study for age-related macular 
degeneration (AMD) in 2,157 cases and 1,150 controls [4]. Our results validate AMD 
susceptibility loci near CFH (P < 10-75), ARMS2 (P < 10-59), C2/CFB (P < 10-20), C3 (P < 
10-9), and CFI (P < 10-6). I compared our top findings with the Tufts/Massachusetts 
General Hospital genome-wide association study of advanced AMD (821 cases, 1,709 
controls) and genotyped 30 promising markers in additional individuals (up to 7,749 
cases and 4,625 controls). With these data, I identified a susceptibility locus near TIMP3 
(overall P = 1.1 × 10-11), a metalloproteinase involved in degradation of the extracellular 
matrix and previously implicated in early-onset maculopathy. In addition, our data 
revealed strong association signals with alleles at two loci (LIPC, P = 1.3 × 10-7; CETP, P 
= 7.4 × 10-7) that were previously associated with high-density lipoprotein cholesterol 
(HDL-c) levels in blood. Consistent with the hypothesis that HDL metabolism is 
associated with AMD pathogenesis, I also observed association with AMD of HDL-c—
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associated alleles near LPL (P = 3.0 × 10-3) and ABCA1 (P = 5.6 × 10-4). Multilocus 
analysis including all susceptibility loci showed that 329 of 331 individuals (99%) with 
the highest-risk genotypes were cases, and 85% of these had advanced AMD. In addition, 
I propose a novel method to facilitate the AMD prediction with GWAS data in general 
population. Our studies extend the catalog of AMD associated loci, help identify 
individuals with a high risk of developing the disease, and provide clues about underlying 
cellular pathways that could eventually lead to new therapies.   
 
Following DNA microarray, NGS technologies allow us to explore more variants beyond 
GWAS. Much progress has been made for efficient and accurate genotype call from NGS 
data and simulations have been performed to study the efficiency and accuracy at 
different sample sizes and sequencing depths. However, most of the current variant 
calling algorithms can only handle unrelated samples; systematic evaluations of 
sequencing data of families are not available up to date. In Chapter 4, I propose an 
efficient and accurate method for genotype calling and haplotype inference in sequencing 
parent-offspring trios. This method combines both linkage disequilibrium (LD) patterns 
and family constraints within the trio together into a widely used hidden Markov model 
in imputation, which takes advantage of similar stretches of chromosomes shared 
between individuals. This method provides a tool of variant calling and haplotype 
phasing for many ongoing sequencing projects that have parent-offspring trios. In 
addition, I am able to explore the potential advantages of sequencing additional family 
members. I simulated shotgun sequencing data in genotype likelihood format (GLF) for 
trios and unrelated samples at various depths with two sequencing error rates. For same 
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number of sequenced samples, our simulations show that sequencing trios are preferable 
to unrelated samples at low depth 1X, 2X and 4X in terms of detecting polymorphic sites. 
Generally, trios have higher calling accuracy across different frequency spectra. 
Furthermore, sequencing trios can greatly increase the haplotyping accuracy, which is 
crucial for follow-up imputation with existing GWAS data.  However, at depth 8X and 
above, the gain of trios are limited and design of unrelated samples are more preferable in 
terms of variant calling. The method can be extended to the designs of nuclear family and 
general pedigree structure.   
 
There have been great successes of linkage disequilibrium (LD) based imputation and 
haplotype haplotype inference methods in detecting additional analysis and performing 
meta analysis across different platforms [4, 8, 9]. A commonly used approach is based on 
a hidden Markov model treating sample haplotype as a mosaic of a pool of reference 
haplotypes [10-14]. The size of the reference panel is usually limited to less than one 
hundred. As the reference panel expands quickly (e.g. 1000 Genomes Project) to a few 
hundred individuals or even more, the computing cost, including time and memory, 
increases as well.  The type of method using full state space thus becomes less feasible in 
practice. On the other hand, the method using approximated reduced state space can be 
applied but will result in losing efficiency and accuracy, especially for genotype calling 
of rare variants. In chapter 5, I propose a state space reduction method to overcome the 
above two limitations. The method defines a set of quantities in a reduced state space to 
keep track of all information in full state space by taking advantage of local similarity 
between different haplotypes. The results from simulation and real data sets show that the 
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new method can substantially save computing memory and time while preserving the 
accuracy of the full sate space method.   
 
In Chapter 6, I will summarize the work of Chapter 2-5 and discuss limitations and future 
plans. In addition, I will describe ongoing effort to address a multiple testing problem.  I 
extend a hidden Markov model based FDR control procedure to account for non-
homogeneous dependency structures. I developed a general EM algorithm for parameter 
estimation. I aim to explore its application in GWAS and sequencing, where hundreds of 
thousands of SNPs are examined with specific dependency structures. 
 
Overall, my research will facilitate current biomedical research in different aspects 
including understanding the biology of retina, accurate genotype calling and haplotype 
inference program for next generation sequencing and improvement of existing 
computational software for imputation and sequencing.  
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Chapter 2  
 
Genome-wide Association Study and Prediction for Age-related Macular 
Degeneration 
 
The content of this chapter has been published in Chen et al. 2010 [4]. 
 
2.1 Introduction 
 
AMD is a progressive neurodegenerative disease and a common cause of blindness in the 
elderly population, particularly in developed countries [15, 16]. The disease affects 
primarily the macular region of the retina, which is necessary for sharp central vision. An 
early hallmark of AMD is the appearance of drusen, which are extracellular deposits of 
proteins and lipids under the retinal pigment epithelium (RPE). As the disease progresses, 
drusen grow in size and number. In advanced stages of AMD, atrophy of the RPE 
(geographic atrophy) and/or development of new blood vessels (neovascularization) 
result in death of photoreceptors and central vision loss [15, 17, 18].  
 
Multiple genetic linkage studies provided strong evidence of susceptibility loci, notably 
on chromosomes 1q31 and 10q36 [19-23]. Disease-associated variants near CFH (1q31) 
and in a cluster of genes near ARMS2 (10q26) were first identified both through 
genomewide association studies (GWAS) [24, 25] and fine mapping of linkage signals 
[26-29]. Discovery of association between AMD and the CFH locus lead researchers to 
discovery of association signals near other complement genes, including C2/CFB, C3, 
and CFI [30-33]. 
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2.2 Genotyping Data 
 
The participants in genome-wide association study were mainly collected at the 
University of Michigan in Ann Arbor (collection coordinated by AS), at the University of 
Pennsylvania in Philadelphia (coordinated by DS), and at the Mayo Clinic in Rochester, 
Minnesota (coordinated by AE). Detailed information about the number of cases and 
controls and the distribution of age, sex and disease severity in each collection is 
summarized in Table 2.1.  
 
Genotyping was performed at the Center for Inherited Disease Research (CIDR) at Johns 
Hopkins University using Illumina Human370 Bead Chips (Illumina, San Diego, CA, 
USA) and the Illumina Infinium II assay protocol [34]. Allele cluster definitions for each 
SNP were determined using Illumina BeadStudio Genotyping Module version 3.2.32 and 
the combined intensity data from 99% of the samples according to CIDR protocol; the 
resulting cluster definitions were then used on all samples. Genotypes were not called if 
the quality threshold (gencall score) was below 0.25. Genotypes were not released from 
CIDR for SNPs which failed technical filters for call rates less than 85%, more than 1 
HapMap replicate error, more than a 4% (autosomal) or 5% (X chromosome) difference 
in call rate between sexes, more than 0.5% male heterozygote frequency for X 
chromosome.  Y and XY SNPs were manually reviewed and clusters adjusted or 
genotypes dropped as appropriate.  Genotypes were released from CIDR for 344,942 
(99.46%) of the attempted SNPs.  Blind duplicate reproducibility was 99.992%.   
 
2.3 Statistical Methods 
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Population Stratification: The samples are all European descent. I used the software 
EIGENSTAT to adjust for the modest population stratification. After adjustment for the 
first two principal components of ancestry, the genomic control parameter was 1.007. 
 
Genotype Imputation: To expand the genome coverage, I performed a genome-wide 
imputation using haplotypes from the HapMap CEU samples as templates (release 22). 
Imputation was done using MACH (Yun Li, www.sph.umich.edu/csg/abecasis/Mach/). 
For downstream analyses, I filtered out poorly imputed SNPs and focused on markers 
with estimated r2 between imputed and true genotypes > 0.3.   
 
Statistical Analyses: To investigate the association between each genotyped or imputed 
SNP and AMD, I first carried out a logistic regression for each SNP assuming an additive 
genetic model and adjusting for the top two eigenvectors from EIGENSTRAT. At p < 10-
6, I identified a total of seven independently associated SNPs in previously reported loci 
(CFH, ARMS2, C3, C2/CFB and CFI). These SNPs were included as covariates in 
logistic regression analyses designed to identify additional loci associated with AMD. 
 
Analysis for Follow-up Study: To combine the statistics across different groups for 
replication, I first selected an arbitrary reference allele for each marker and then 
calculated a z-statistic summarizing the evidence for association in each study 
(summarizing both the p-value, in its magnitude, and the direction of effect, in its sign). I 
then calculated an overall z-statistic as a weighted average of the individual statistics and 
calculated the corresponding p-value. Weights were proportional to the square root of the 
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number of individuals examined in each study and were selected such that the squared 
weights sum up to 1.0. 
 
Association Testing: For samples including unrelated individuals only (all discovery 
samples, the Tufts/MGH samples and the Johns Hopkins, Oregon and Penn-NJ sample 
sets) the data were analyzed using simple logistic regression models with age and sex as 
covariates. For the discovery samples, the first two principal components of ancestry 
were used as covariates in all reported analyses and genotypes for the markers listed in 
Table 2.2 were used as covariates in a subset of the analyses (described in the text). For 
follow-up samples, genotypes at CFH and ARMS2 were included as covariates where 
available. For samples including related individuals, the data were analyzed with the test 
of Thornton and McPeek [35]. 
 
Risk Prediction Approach.  To evaluate the cumulative contribution of the alleles 
identified here to disease risk, I fitted a simple logistic regression model to the data. The 
effect of each genotype was modeled on a log-additive scale, with no interaction terms 
between genotypes:
  
Then fitted probability   is calculated for each sample      
I sorted samples according to their fitted probability of disease and organized individuals 
into deciles of fitted risk yi. Then I counted the proportion of affected individuals in each 
risk decile. In a subsequent analysis, I assigned different weights to cases and controls, 
designed to reflect the fact that cases are enriched in our sample. The weight is defined as  
 
∑+=
j
ijji x)it(y βαlog
)1/(1ˆ
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and weighted fitted probability is defined as  
where pcase = 0.65 and pcontrol = 0.35 are the fractions of cases and controls in our sample 
and fcase = 0.20 and fcontrol = 0.80 are the expected fractions of cases and controls in an 
elderly population at age ~75. Cases were assigned weight fcase /pcase and controls were 
assigned weight fcontrol/pcontrol. I sort zi in an ascending order and denote as z(1),z(2),…,z(m) 
with corresponding weight w(1),w(2),…,w(m). Taking these weights into account, I then 
divided the sample into deciles ensuring that summed weights in each decile were 
identical. zi is used to estimate the case fraction in general population.  
 
2.4 Results and Discussion 
 
 
The execution of progressively larger GWAS typically results in the gradual discovery of 
new susceptibility loci (see the examples of Crohn’s disease [36], type 2 diabetes [37], 
obesity [38], and lipids [5, 39]). To identify additional susceptibility loci and biochemical 
pathways contributing to AMD, I performed GWAS in a large collection of cases and 
controls (Table 2.1) using a genotyping platform that captures >90% of common variants 
in European ancestry samples. 
 
I genotyped study samples, including 75 blind duplicates, together with HapMap controls 
at the Center for Inherited Disease Research (CIDR, Johns Hopkins) with Illumina 
Human370 chips. After genotyping, I excluded 18 individuals with an unexpected 1st or 
2nd degree relative in the dataset and 13 individuals with evidence for a non-European 
iii ywz ˆ=
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ancestry component[40] resulting in a total of 2,157 unrelated cases and 1,150 unrelated 
controls for analyses. I excluded markers with <95% call rate, minor allele frequency 
<1%, or evidence for deviation from Hardy-Weinberg equilibrium at p<10-6, resulting in 
a total of 324,067 autosomal SNPs for analysis. The average call rate for analyzed 
markers and samples was 99.94%. I identified short stretches of haplotype shared 
between individuals in our study and those in the HapMap CEU [41] and used these to 
impute missing genotypes, expanding the number of analyzed SNPs to about 2.5 million 
imputed or genotyped SNPs. Complete GWAS data and results are available from dbGaP 
accession phs000182.v1.p1. 
 
An initial comparison of allele frequencies between cases and controls resulted in a 
genomic control parameter [42] of 1.056; adjustment for the first two principal 
components of ancestry [PCA, 40] reduced this to 1.007. PCA can account for subtle 
differences among European ancestry samples (such as North-South or East-West 
gradients in allele frequency, see [43]) and provide a useful safeguard against population 
stratification. All results reported here refer to this PCA adjusted analysis.  
 
Reassuringly, I observed strong evidence of association at established susceptibility loci 
(see Table 2.2, Figure 2.1 and 2.2); near CFH (strongest association at rs10737680, odds 
ratio 3.11(2.76, 3.51), with p<1.6x10-75), near ARMS2 (at rs3793917, OR=3.40 
(2.94,3.94), p=4.1x10-60), near complement component 2 (C2) and complement factor B 
(CFB) (at rs429608, OR=2.16 (1.84,2.53), p=2.5x10-21), and near complement 
component 3 (C3) (at rs2230199, OR=1.74 (1.47,2.06), p=1.0x10-9). Our study provides 
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confirmation of a recently reported association between AMD and complement factor I 
(CFI) (at rs2285714, OR=1.31 (1.18,1.45), p=3.4x10-7) [30]. Conditioning on the 
strongest associated variant at each of these loci identified additional, strong association 
signals near CFH (at rs1329424, p=6.4x10-16) and in the C2/CFB locus (at rs9380272, 
p=2.3x10-8), consistent with previous reports of multiple disease-associated alleles at the 
two loci [29, 31, 44, 45]. Where possible, I evaluated evidence for association at other 
previously suggested susceptibility loci using genotypes or imputed data. The results are 
summarized in Table 2.5; although none of these loci show p<.05 in our data, note that 8 
of 9 signals trend in the same direction as the original report. 
 
To identify new AMD susceptibility loci, I conditioned on the seven strongly associated 
SNPs (see Table 2.2) and repeated the genomewide analysis. No single SNP was 
significant at p<5x10-8 in this conditional analysis. Next, I exchanged initial results with 
the Tufts/MGH GWAS for 1358 SNPs that could be assayed directly with Affymetrix 6.0 
genotyping arrays and that were significant at p<.001 in either study. Tufts/MGH GWAS 
results were adjusted for possible population stratification using genomic control[42], 
consistent with the analysis presented in the companion paper. After excluding 158 
AREDS study participants that were genotyped in both studies, this allowed us to 
examine promising SNPs in an additional 821 cases with geographic atrophy or 
neovascularization and 1,709 controls. Twenty-five SNPs showing consistent evidence of 
association in both groups of participants and five other SNPs with strong evidence for 
association in our data alone were genotyped in additional samples (see Table 2.1). 
Summary results from follow-up experiments are presented in Table 2.6. Detailed results 
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for the three most strongly associated loci (near TIMP3, CETP, and LIPC) and two other 
loci discussed below (LPL, ABCA1) are provided in Table 2.7.  
To validate our results, I examined Hardy-Weinberg equilibrium statistics and evidence 
for heterogeneity at these new loci. I also genotyped a subset of the imputed SNPs in our 
discovery sample. At each of these loci, Hardy-Weinberg equilibrium p-values in cases, 
in controls and in the combined dataset were all >.20, suggesting no data quality 
problems. Furthermore, I found no evidence for heterogeneity at any of these loci (all 
Cochran's Q heterogeneity p-values >.20). Finally, when I genotyped a subset of the 
1,161 samples for 6 of the imputed SNPs near TIMP3 (our strongest new locus), I 
observed >99.4% concordance between imputed and genotyped alleles. Association 
results for this set of individuals were essentially the same whether imputed or actual 
genotypes were used for analysis. A comparison of results with genotyped and imputed 
SNPs at each locus is given in Table 2.8. 
 
Our strongest new locus maps near TIMP3 and SYN3 on chromosome 22 (see Fig. 3, top 
panel, and Table 2.3). There, I found that very common alleles (frequency of ~.94 in 
controls) at rs9621532 and nearby markers were associated with increased risk of AMD 
(OR=1.41 (1.27,1.57), overall p=1.1x10-11, one sided p-value in newly genotyped follow-
up samples pfollow-up=3.3x10-7). Consistent with the expectation that GWAS tend to 
estimate effect sizes (the “winner’s” curse effect), I found that odds-ratios estimates in 
the discovery samples were larger than in the follow-up samples [46]. Results at the 
TIMP3 locus were robust to a variety of analysis models (including different 
combinations of PCA, adjustment for previously known loci, and inclusion of age and 
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sex as covariates, see Table 2.9), are supported by nearby directly genotyped SNPs (see 
Table 2.8), and remain significant when data from the companion paper are excluded 
from analysis (overall p=7x10-11 excluding all Tufts/MGH data).  
 
Two other loci also exhibited strong evidence for association. Near LIPC on chromosome 
15, the common allele at rs493258 (frequency of ~.53 in controls) was associated with 
increased risk of AMD (OR=1.14 (1.09,1.20), overall p=1.3x10-7, pfollow-up=.0012). Near 
CETP on chromosome 16, the rare allele at rs3764261 (frequency ~.36 in controls) was 
associated with increased risk of AMD (OR=1.19 (1.12,1.27), overall p=7.4x10-7, pfollow-
up=.009). The signals near CETP and LIPC do not reach p <5x10-8, corresponding to 
genomewide significance after adjustment for one million independent tests. However, 
note that: (a) both LIPC and CETP show nominally significant association in follow-up 
samples alone; (b) less than 0.3 loci per scan are expected to reach p < 3x10-7 by chance, 
suggesting that one or both of these signals are real; (c) LIPC association with AMD 
reaches genomewide significance in a companion paper; (d) in a sample of Japanese 
individuals, top SNPs at CETP (p=.001), LIPC (p=.10) and TIMP3 (p=.09) trend in the 
right direction (see Table 2.7). 
 
Additional experiments will be required to identify the functional alleles at each locus 
and the genes/pathways they impact. The challenges in identifying functional alleles are 
illustrated by the controversy over causal alleles near ARMS2 (where the PLEKHA1, 
ARMS2, and HTRA1 genes have been implicated [25-27, 47, 48]) and CFH (where non-
coding variants may contribute to disease [44, 45] independently of the Y402H coding 
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variant that was the initial focus of attention). Despite these caveats, the new loci reported 
here suggest biological pathways influencing disease susceptibility and possibly new 
therapies.  
 
Our top novel signal maps to a large intron of the synapsin III (SYN3) gene involved in 
neurotransmission and synapse formation [49]. The SNP is located about 100 kb 
upstream of TIMP3, a metalloproteinase encoded within the same intron of SYN3. TIMP3 
is involved in degradation of the extracellular matrix and mutated in Sorby's Fundus 
Dystrophy [50], an early onset macular degenerative disease that shares clinical features 
with AMD but typically presents before age 40. Sorby's is extremely rare, presents with a 
highly penetrant autosomal dominant family history, and unlikely to be misclassified as 
AMD. When I excluded all patients with age of onset <60 from our sample, evidence for 
association at TIMP3 was essentially unchanged. Linkage of AMD to the TIMP3/SYN3 
region has been reported previously [22]. The effects of the common alleles reported here 
are too small to account for the observed linkage signal, but it is possible that missed rare 
high penetrance alleles could reside in the same locus and explain the linkage.  
 
Outside known loci and TIMP3, our two strongest signals are located near the hepatic 
lipase (LIPC) gene on chromosome 15q22 (initial evidence of association at rs493258 
came from Tufts/MGH GWAS) and the cholesterylester transfer protein (CETP) gene on 
16q21. The AMD associated alleles at these loci have been associated with HDL-c levels 
in blood [5, 39]. This prompted us to examine whether other common HDL-c associated 
polymorphisms might contribute to AMD risk. The three common alleles showing 
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strongest association to blood HDL-c levels in an analysis of 19,840 individuals [5] also 
reveal evidence of association with AMD in our discovery cohort (rs173539 near CETP 
with p=2.4x10-6; rs12678919 near LPL with p=.0016; rs10468017 near LIPC with 
p=.0018). Table 2.4 and Suppl. Fig. 1 show that the same clusters of SNPs (colored) 
associated with HDL-C (each cluster has lead SNP with p < 5x10-8) are associated with 
macular degeneration; association signals are sharper for HDL-C given the much larger 
sample sizes (and greater power) of that analysis. Multiple common alleles near CETP 
and LIPC are associated independently with HDL-c levels [5]. In our sample, I find 
modest association of the secondary HDL-associated alleles in each of these loci with 
AMD (rs289714 near CETP with p=.062; rs2070895 near LIPC with p=.051). Finally, 
HDL-associated alleles near ABCA1 also show evidence of association with AMD 
(rs1883025, p=.0026). The probability that four or more of the 14 reported HDL-
associated alleles [5] would show association with AMD with p<.0026 is extremely low 
(4x10-8), and the probability that the top three HDL- associated alleles would reveal 
association with p<.0018 is 6x10-9 (the probability of p<.14 or better, as in the replication 
samples alone, is .003). Importantly, since I found association specifically for alleles with 
the largest impact on HDL levels, it seems likely that additional signals may have been 
missed due to lack of power. Just as for CETP and LIPC, association signals at LPL and 
ABCA1 were consistent in follow-up samples and discovery samples; combining all 
available data I observed association with p=3.0x10-3 near LPL and 5.6x10-4 near ABCA1 
(Table 2.4).  
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Cholesterol and lipids accumulate underneath the RPE with age [51] and are present in 
the drusen that characterize early AMD [52, 53]. Genetic variants that impact cholesterol 
levels in the macula and RPE might impact drusen formation and thus modulate the risk 
of AMD. Since alleles near CETP and LPL associated with decreased HDL-c levels in 
blood appear to increase the risk of AMD, but alleles near LIPC and ABCA1 associated 
with decreased HDL-c levels in blood appear to decrease the risk of AMD, I speculate 
that some alleles impact cholesterol levels in blood and in the macula in opposite 
directions. For example, a variant that impacts cholesterol transport between tissues could 
facilitate transport of HDL-c from the macula to the blood (or vice-versa). CETP and 
LPL play major roles in the synthesis and degradation of HDL-c, whereas LIPC and 
ABCA1 are involved in mediating the uptake of HDL-c at the cell surface. Previously, 
epidemiological studies have indicated a link between cardiovascular risk factors 
(including HDL-c) and incidence of AMD [54, 55], but these findings have not been 
definitive. Our data therefore suggest an important role for HDL-c metabolism in AMD 
pathogenesis but also that (a) blood HDL-cholesterol levels may be a poor surrogate for 
the impact of HDL-c on disease risk and that (b) further work is needed to characterize 
the relationship between AMD and HDL-c associated alleles. It would be particularly 
interesting to examine samples with information on AMD classification and direct 
measurements of HDL-c levels in the retina.  
 
To investigate whether identified risk alleles contributed preferentially to one disease 
subtype, I carried out a series of subgroup comparisons (Table 2.10). When I compared 
different case subgroups, I found ARMS2 risk alleles were more common in cases with 
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neovascular disease than in cases with large drusen (OR=1.79 (1.50-2.13), p=4.3x10-11) 
or with geographic atrophy (OR=1.36 (1.13-1.63), p=.0009). In contrast, CFH risk alleles 
were more common in cases with geographic atrophy than in those with large drusen 
(OR=1.38 (1.11-1.73), p=.0012) or neovascular disease (OR=1.32 (1.08-1.64), p=.009). 
Risk alleles near other complement genes appeared to be somewhat more common in 
cases with geographic atrophy than in those with neovascularization, whereas the reverse 
was true for risk alleles near TIMP3 (differences not significant). In our discovery 
sample, I tested for, but did not find, evidence of interactions between associated alleles 
at the seven loci listed in Tables 2.2 and 2.3. I also tested for, but did not find, significant 
interactions of risk alleles with sex and smoking. 
 
Although the other GWAS paper did not identify TIMP3, targeted follow-up of the 
markers identified in our scan confirms our findings. The difference in the initial results 
of the two studies derives from different choices of markers to follow-up after the initial 
GWAS: a costly experiment with maximum power would involve genotyping all 
discovery and follow-up samples for all markers. Practical considerations meant that each 
study could only examine a subset of interesting markers in available follow-up samples. 
Ultimately, I expect that further genotyping of follow-up samples and meta-analysis of 
our results with those of future GWAS will identify more disease susceptibility loci. The 
variants identified here have only a modest impact on the risk of age-related macular 
degeneration. However, they do point to potentially important biological targets (such as 
the TIMP3 gene and HDL-cholesterol), whose effectiveness for therapeutic intervention 
remains to be evaluated. I note that genes like IL23 and HMGCR2 are extremely effective 
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drug targets (for the treatment of psoriasis and for LDL-cholesterol lowering medications, 
respectively) despite the fact that naturally occurring common variants in the 
corresponding loci account for only small changes in the risk of psoriasis [56] and in 
blood lipid levels [5], respectively. 
 
Genetic susceptibility variants may be used to predict individual risk of AMD [57, 58]. 
To evaluate the effectiveness of the approach, I fitted a simple logistic regression model 
to the data. The model included the SNPs listed in Tables 2.2, 2.3 and 2.4 as predictors. 
For each SNP, a single variable encoding the number of risk alleles was modeled; no 
interaction terms or dominance effects were considered. In effect, the model calculates a 
weighted sum of risk alleles for each individual (with weights proportional to the log 
odds-ratio for each allele) and assigns individuals with large weighted sums the largest 
risk. Among the 331 individuals (10% of our sample) with the highest risk genotypes 
only 2 are controls and 329 are cases (see Fig. 5, top panel, for information on other 
genotype risk bands). Assuming a disease prevalence of 20% at age ~75, I predict that 
~80% of individuals with genotypes in the top decile of risk will develop AMD, but <5% 
of individuals in the bottom 3 deciles will develop disease (see Fig. 5, bottom panel). 
Furthermore, I find that, among cases, individuals with high risk genotypes will present 
with severe disease more often (in the top risk decile for our sample, 15% of our cases 
have large drusen, 22% geographic atrophy and 63% have neovascularization) than 
individuals with lower risk genotypes (in the bottom risk decile, 51% of cases have large 
drusen, 19% geographic atrophy only and 30% have neovascularization). A productive 
strategy to identify rare alleles that impact disease susceptibility might involve a detailed 
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examination of DNA sequences in individuals with severe disease but whose common 
variant genotypes predict low disease risk.  
 
Despite these encouraging contrasts between individuals with low and high risk 
genotypes, AMD susceptibility alleles must be evaluated in population-based cohorts 
before genotypes can become routine diagnostic tools [58]. While trends pointing to 
increased frequency of severe disease in individuals with high-risk genotypes should 
hold, the absolute risk of developing severe disease is difficult to estimate accurately in 
samples collected in tertiary clinics. In the meantime, our results point to new molecular 
pathways and encourage new directions in the search for treatment and prevention of this 
common blinding disease. 
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Table 2.1 Summary description of discovery samples used in the genome-wide association and replication studies 
 
     Cases     Controls  
  N 
Male 
(%) 
Age 
(Average) 
Large Drusen  
(%) 
Geographic Atrophy 
(%) 
Neovascular 
(%)   N 
Male 
(%) 
Age 
(Average) 
 
Total 
Discovery Samples             
Michigan 786 36.9 79.8 14.2 21.6 64.2  516 41.5 76.6  1,302 
Mayo Clinic 535 36.1 77.3   46.5 13.6 39.8  433 46.7 70.2     968 
AREDS 440 41.0 80.8 none genotyped 26.8 73.2      0      0      0     440 
Pennsylvania 396 40.4 75.7 42.7 26.3 31.0   201 45.3    76     597 
Total  2,157 38.2 78.6 24.5 21.6 53.9  1,150 44.1 74.1  3,307 
Parallel Discovery Samples            
Tufts/MGH† 821 46.0 80.3 none genotyped 27.5 72.5  1,709 46.0 76.0  2,530 
Replication Samples             
Pittsburgh*  1,308 36.7 69.9 9.7* 18.9 70.0  229 49.8 76.7  1,537 
Miami/Duke/Vanderbilt  1,157 35.1 75.7 28.3 13.6 58.2  514 40.5 68.4  1,671 
Tufts/MGH II 868 40.0 79.7 none genotyped 28.3 71.7  789 40.0 73.0  1,657 
Johns Hopkins* 665 32.8 75.5 21.8* 12.4 57.2  131 31.3 74.7     796 
Penn-NJ 556 39.8 79.8 19.1 6.8 65.5  347 47.0 75.6     903 
Oregon  515 34.0 79.8 none genotyped 27.2 72.8  263 45.0 74.0     778 
Massachusetts E. E. I. 391 40.4 76.0 10.5 1.3 73.6  194 44.6 75.4     585 
Spain (IDIS-Sgo) 353 46.2 76.7 none genotyped 16.1 83.9  282 44.7 75.1     635 
Case Western Reserve  1,258 43.5 78.5 32.6 9.2 40.5    1,540 50.7 72.5  2,798 
Total  7,071 41.1 76.2 14.9 14.0 65.8  4,289 45.5 73.0  11,360 
Non-European 
Samples           
 
 
Japan 678 69.0 74.8 none genotyped 0.0 100.0  336 42.0 74.2  1,014 
Grand Total* 10,727 40.9 77.0 15.7 16.6 64.0  7,484 45.3 73.9  18,211 
*Proportions of cases with large drusen, geographic atrophy, and neovascular disease do not add up to 100.0% because 8.6% of cases from Johns Hopkins and 0.4% of cases from 
Pittsburgh had intermediate drusen. †The Tufts/MGH samples used here exclude 158 AREDS samples that overlap with our discovery sample.  
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Table 2.2 Confirmation of previously reported association signals in the discovery samples 
 
     
Position 
(basepair) 
 
Notable Nearby  
Genes 
 
Alleles 
   
Frequency (risk allele) 
 
OR 
 
p-value 
 
 
SNP Chrom. (risk/non-risk)   Cases  Controls λsib 
Primary Association Signals  
rs10737680* 1 194,946,078 CFH A/C  0.801 0.566 3.11 (2.76, 3.51) 1.6 × 10-76 1.24 
rs3793917* 10 124,209,265 ARMS2/HTRA1 G/C  0.371 0.164 3.40 (2.94, 3.94) 4.1 × 10-60 1.45 
rs429608 6 32,038,441 C2/CFB G/A  0.920 0.842 2.16 (1.84, 2.53) 2.5 × 10-21 1.05 
rs2230199* 19 6,669,387 C3 C/G  0.224 0.163 1.74 (1.47, 2.06) 1.0 × 10-10 1.06 
rs2285714 4 110,858,259 CFI T/C   0.464 0.395 1.31 (1.18, 1.45) 3.4 × 10-7 1.02 
Secondary Association Signals  
rs1329424* 1 194,912,799 CFH T/G  0.603 0.351 1.88 (1.68, 2.10) 6.4 × 10-16 1.11 
rs9380272* 6 32,013,989 C2/CFB A/G  0.016 0.012 4.31 (2.76, 6.87) 2.3 × 10-8 1.12 
 
 
 
Association peaks at previously reported loci. For two of these loci (near CFH and C2/CFB), I found significant secondary signals after adjusting for the strongest initial signal. At 
C2/CFB locus, rs9380272 shows no significant association before adjusting for the primary signal because its risk allele is in linkage disequilibrium with the protective allele at 
rs429608. Conditioning on either of these two SNPs enhances the signal at the other SNP. The recurrence risk ratio λsib quantifies the increase in risk to siblings of affected 
individuals attributable to a specific allele. For example, a λsib of 1.24 implies that alleles at the first locus are responsible for 24% increase in risk to siblings of AMD patients 
compared to the general population. *(imputation r2 > 0.95). 
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Table 2.3 New Locus with Confirmed Association to AMD (p < 5x10-8) 
  Position 
(basepair) 
Notable Nearby 
Genes 
Alleles         Frequency (risk allele) 
OR p-value§ λsib SNP Chrom. (risk/non-risk)  Cases Controls 
rs9621532 22 31,414,511 SYN3/TIMP3 A/C       
 Discovery sample (2,157 cases, 1,150 controls) …  0.964 0.943 1.81 (1.42, 2.29) 3.9 × 10-5 1.011 
 Tufts/MGH sample (821 cases, 1,709 controls) …  0.959 0.947 1.31 (0.98, 1.74) 0.008 * 1.004 
 De novo replication sample (7,071 cases, 4,289 controls) …  0.959 0.947 1.33 (1.17, 1.52) 3.3 × 10-7 1.008 
Combined sample (10,049 cases, 7,148 controls) …  0.960 0.946 1.41 (1.27, 1.57)   1.1 × 10-11 1.008 
      Cochran's Q Heterogeneity Test P-value = 0.245 
 
This table summarizes results for a new confirmed association signal near TIMP3 (overall p < 5x10-8; corresponding to an adjustment for ~1 million independent tests). 
*Excluding overlapping AREDS samples in the Tufts/MGH study. §P-values for the discovery and combined samples are two sided. P-values for the Tufts/MGH and de novo 
replication samples are one sided. 
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Table 2.4 Association of HDL-C loci with AMD 
  Position 
(basepair) 
Notable Nearby 
Genes 
Alleles  Frequency (risk allele) 
OR p-value§ SNP Chrom. (risk/non-risk)   Cases  Controls 
rs493258 15 56,475,172 LIPC C/T      
                Discovery sample (2,157 cases, 1,150 controls) …  0.564 0.528 1.21 (1.10, 1.34) 0.002 
          Tufts/MGH sample (821 cases, 1,709 controls) …  0.579 0.524 1.25 (1.11, 1.41) 2.8 × 10
-4
 * 
De novo replication sample (5,914 cases, 3,775 controls) ...  0.562 0.575 1.10 (1.03, 1.16) 0.001 
  Combined sample (8,892 cases, 6,634 controls) …  0.563 0.564 1.14 (1.09, 1.20) 1.3 × 10
-7 
      Cochran's Q Heterogeneity Test P-value = 0.64 
rs3764261 16 55,550,825 CETP A/C      
 Discovery sample (2,157 cases, 1,150 controls) …  0.364 0.314 1.36 (1.26, 1.46) 1.7 × 10
-6 
        Tufts/MGH sample (821 cases, 1,709 controls) …  0.356 0.329 1.13 (1.00, 1.28) 0.070 
 De novo replication sample (4,945 cases, 1,960 controls) …  0.347 0.317 1.10 (1.00, 1.22) 0.009 
Combined sample (7,923 cases, 4,819 controls) …  0.354 0.316 1.19 (1.12, 1.27) 7.4 × 10
-7 
      Cochran's Q Heterogeneity Test P-value = 0.65 
rs12678919 8 19,888,502 LPL G/A      
 Discovery sample (2,157 cases, 1,150 controls) …  0.115 0.096 1.38 (1.17, 1.63) 0.002 
 De novo replication sample  (3,333 cases, 1,288 controls) …  0.113 0.108 1.11 (0.92, 1.35) 0.140 
Combined sample (5,490 cases, 2,438 controls) …  0.114 0.102 1.26 (1.11, 1.43) 0.003 
  Cochran's Q Heterogeneity Test P-value = 0.893 
rs1883025 9 106,704,122 ABCA1 C/T      
 Discovery sample (2,157 cases,  1,150 controls) …  0.739 0.705 1.25 (1.12, 1.40) 0.003 
 De novo replication sample (4,982 cases, 3,022 controls) …  0.752 0.741 1.10 (1.00, 1.19) 0.019 
Combined sample (7,139 cases, 4,172 controls)…  0.747 0.731 1.15 (1.07, 1.23) 5.6 × 10-4 
  Cochran's Q Heterogeneity Test P-value = 0.51 
* Excluding overlapping AREDS samples in the Tufts/MGH study. Before excluding these samples, Tufts/MGH results differ slightly (for example, p-value at rs493258 was 
2.2x10-5). §P-values for the discovery and combined samples are two sided. P-values for the Tufts/MGH and de novo replication samples are one sided. 
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Table 2.5 Association results of some published candidate SNPs in our scan 
                
Gene SNP RiskAllele/Other 
P-value 
In  
Original  
Report Original Report 
P-value in 
Discovery 
Sample 
P-value in 
Discovery  
Sample, 
After Adjusting 
For Known Loci 
Direction 
Of  
Effect,  
Vs. 
Original  
Report 
TLR3 rs3775291 C/T 1.2 × 10-7 Yang Z et al. NEJM 2008 0.526 0.885 opposite 
TLR4 rs4986790 G/A 0.001 Zareparsi S et al. HMG 2005 0.552 0.091 same 
SERPING1 rs2511989 G/A 7.5 × 10-8 Ennis S et al. Lancet 2008 0.944 0.923 same 
ERCC6 rs3793784 G/C 0.020 Tuo J et al. PNAS 2005 0.961 0.480 same 
LRP6 rs7294695 C/G 0.020 Haines JL et al. IOVS 2006 0.543 0.867 same 
CX3CR1 rs3732378 A/G 0.002 Tuo J et al. FASEB J. 2004 0.150 0.100 same 
IL8 rs4073 T/A 0.037 Goverdhan SV et al. Br. J. Ophthalmol 2008 0.578 0.301 same 
VEGF rs2010963 C/G 0.020 Haines JL at al. Invest Ophthalmol Vis Sci. 2006 0.302 0.320 same 
VLDLR rs2290465 C/G 0.010 Haines JL at al. Invest Ophthalmol Vis Sci. 2006 0.782 0.402 same 
        
Previously associated SNPs near APOE and ABCA4 are not listed because they were not genotyped in our sample and could not be imputed confidently using either 1000 
Genomes or HapMap reference haplotypes. 
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Table 2.6 Complete Results for All SNPs Where Replication Attempted 
SNP 
Risk/ 
Nonrisk GWAS 
Tufts/MGH 
GWAS 
Tufts/MGH 
Replication JHU Penn-NJ Oregon 
Spain 
IDIS MEEI 
Case 
Western Pitt 
Miami 
Duke 
Vanderbilt Japan Combined 
rs9621532 A/C 3.9 × 10-5 0.008 0.175 0.005 0.001 0.018 0.249 0.060 0.150 0.006 0.037 0.093 1.1 × 10-11 
rs493258 C/T 2.1 × 10-3 0.0003 0.062 0.045 0.229 0.118 0.456 0.441 0.095 0.052 -- 0.101 1.3 × 10-7 
rs3764261 A/C 1.7 × 10-6 0.070 -- 0.866 0.153 0.114 0.126 0.166 -- 0.530 0.007 0.004 7.4 × 10-7 
rs2958154 C/T 3.8 × 10-5 0.475 -- -- -- -- -- 0.453 -- 0.950 0.039 -- 2.0 × 10-6 
rs11878133 T/C 3.5 × 10-4 0.002 -- -- -- -- -- 0.136 -- 0.531 0.091 -- 4.4 × 10-6 
rs2142541 T/G 6.5 × 10-5 0.035 -- -- -- -- -- 0.265 -- 0.459 0.044 -- 1.1 × 10-5 
rs17628762 A/C 8.6 × 10-3 0.0002 -- -- -- -- -- 0.080 -- 0.001 0.932 -- 2.4 × 10-5 
rs6022766 A/C 1.5 × 10-2 0.0005 -- -- -- -- -- -- -- 0.439 0.073 -- 3.3 × 10-5 
rs9973159 C/T 2.0 × 10-3 0.010 0.485 -- -- 0.071 -- -- 0.095 0.453 0.071 -- 4.4 × 10-5 
rs2127740 A/G 1.6 × 10-3 0.493 -- -- -- -- -- 0.100 -- -- 0.361 -- 5.2 × 10-5 
rs6484926 A/G 6.5 × 10-5 0.012 0.053 0.495 -- 0.875 -- -- 0.060 0.385 0.520 -- 6.3 × 10-5 
rs6982567 T/C 9.5 × 10-7 -- 0.060 0.162 -- 0.242 -- 0.375 0.100 0.047 0.845 -- 8.9 × 10-5 
rs10103849 A/G 5.2 × 10-6 0.003 -- 0.265 -- 0.649 -- -- 0.425 0.621 0.560 -- 1.7 × 10-4 
rs 8052081 G/C 3.8 × 10-5 0.024 -- -- -- -- -- -- -- 0.417 0.636 -- 2.0 × 10-4 
rs655464 G/A 1.9 × 10-3 0.004 -- -- -- -- -- -- -- 0.631 0.322 -- 2.7 × 10-4 
rs13142235 A/G 6.9 × 10-5 0.045 -- -- -- -- -- -- -- -- 0.675 -- 4.1 × 10-4 
rs1884807 G/A 8.3 × 10-4 0.002 -- -- -- 0.711 -- -- -- 0.113 0.923 -- 5.2 × 10-4 
rs1883025 C/T 2.6 × 10-3 -- -- -- -- 0.020 0.119 0.798 0.135 0.109 0.429 -- 5.7 × 10-4 
rs7737931 C/G 8.6 × 10-5 0.055 -- -- -- -- -- -- -- 0.382 0.638 -- 6.5 × 10-4 
rs12914520 T/C 1.3 × 10-3 0.002 -- 0.050 -- 0.84 -- -- -- 0.466 0.714 -- 7.6 × 10-4 
rs7704053 A/G 5.7 × 10-2 0.0001 -- -- -- -- -- -- -- 0.631 0.353 -- 7.7 × 10-4 
rs17121872 A/G 1.3 × 10-4 0.003 -- -- -- -- -- -- -- 0.908 0.825 -- 1.0 × 10-3 
rs16848791 G/T 1.4 × 10-4 0.006 0.343 0.139 -- 0.319 -- 0.841 0.305 0.834 0.549 -- 1.3 × 10-3 
rs10468017 C/T 1.8 × 10-3 -- -- -- 0.170 0.105 0.671 0.365 -- 0.050 0.484 -- 1.5 × 10-3 
rs12678919 G/A 1.8 × 10-3 -- -- -- -- 0.392 0.416 -- -- 0.243 0.193 0.334 3.2 × 10-3 
rs12001032 T/C 8.5 × 10-4 0.023 0.751 -- -- 0.302 -- -- -- 0.112 0.779 -- 5.4 × 10-3 
rs2892715 G/A 8.5 × 10-6 0.711 -- -- -- -- -- 0.872 -- 0.642 0.401 -- 2.0 × 10-2 
rs6445063 C/T 1.4 × 10-5 0.814 -- -- -- -- -- -- -- 0.446 0.667 -- 2.8 × 10-2 
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Table 2.7  Sample by Sample Results for Newly Reported Loci 
PART 1/3 
 
rs9621532 (A/C) near TIMP3 
   Cases       Controls    
OR P   A/A  A/C C/C P(A)   A/A A/C C/C P(A)   
Discovery 2005 149 3 0.964  1022 125 3 0.943  1.81 (1.42, 2.29) 3.9 × 10-5 
Tufts/MGH 732 62 4 0.957  1466 163 3 0.947  1.31 (0.98, 1.74) 0.016 
Tufts/MGH II 777 69 4 0.955  703 75 1 0.951  1.09 (0.85, 1.51) 0.350 
Johns Hopkins 626 37 1 0.971  113 16 0 0.938  2.21 (1.22, 4.03) 0.008 
Penn-NJ 510 46 0 0.959  295 52 0 0.925  1.90 (1.26, 2.86) 0.002 
Oregon 452 24 0 0.975  229 23 0 0.954  1.88 (1.05, 3.37) 0.036 
Spain(IDIS-Sgo) 330 17 0 0.976  259 17 0 0.969  1.27 (0.64, 2.50) 0.498 
Massachusetts E.E. I.** 345 39 0 0.949  163 26 1 0.926  1.49 (0.90, 2.46) 0.119 
Case Western Reserve 1124 95 8 0.955  1370 147 3 0.950  1.12 (0.87, 1.44) 0.300 
Pittsburgh** 169 10 0 0.972  130 10 1 0.957  1.55 (0.66, 3.63) 0.011 
Miami/Duke/Vanderbilt** 629 69 4 0.945  218 30 1 0.936  1.18 (0.77, 1.81) 0.074 
             
Japan 617 37 1 0.970   303 27 0 0.959   1.38 (0.84, 2.28) 0.195 
             
Test of heterogeneity:      Q  d.f. p.value          
  11.47 9 0.2448          
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PART 2/3 
rs493258 (C/T) near LIPC 
   Cases    Controls     
    C/C C/T T/T P( C)   C/C C/T T/T P( C)   OR P 
 Discovery 691 1053 413 0.564  323 569 258 0.528  1.21 (1.10, 1.34) 0.002 
 Tufts/MGH 260 391 147 0.579  470 782 380 0.524  1.25 (1.11, 1.41) 0.001 
 Tufts/MGH II 254 428 172 0.548  213 387 182 0.520  1.12 (0.98, 1.29) 0.124 
 Johns Hopkins 203 315 119 0.566  35 58 33 0.508  1.26 (0.96, 1.66) 0.090 
 Penn-NJ 193 273 90 0.593  110 179 58 0.575  1.08 (0.89, 1.31) 0.458 
 Oregon 167 228 104 0.563  78 111 63 0.530  1.14 (0.92, 1.42) 0.235 
 Spain(IDIS-Sgo) 104 164 79 0.536  82 128 64 0.533  1.01 (0.81, 1.27) 0.911 
 Massachusetts E.E. I.** 128 159 88 0.553  52 88 35 0.549  1.02 (0.79, 1.31) 0.822 
 Case Western Reserve 366 595 217 0.563  404 726 300 0.536  1.12 (1.00, 1.24) 0.190 
 Pittsburgh** 66 70 39 0.577  52 64 35 0.556  1.09 (0.80, 1.49) 0.104 
 Miami/Duke/Vanderbilt** 222 337 131 0.566  65 149 31 0.569  0.99 (0.80, 1.21) -- 
              
  Japan 35 200 408 0.210   10 102 217 0.185   1.17 (0.94, 1.46) 0.202 
              
 Test of heterogeneity:      Q  d.f. p.value          
    6.96 9  0.6412           
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rs3764261 (A/C) near CETP 
   Cases    Controls     
    A/A A/C C/C P(A)   A/A A/C C/C P(A)   OR P 
 Discovery 296 979 882 0.364  118 486 546 0.314  1.36 (1.26, 1.46) 1.7 × 10-6 
 Tufts/MGH 104  377     340 0.356  216 784 709 0.329  1.13 (1.00, 1.28) 0.140 
 Tufts/MGH II -- -- -- --  -- -- -- --  -- -- 
 Johns Hopkins 87 293 261 0.364  24 50 48 0.402  0.85 (0.70, 1.04) 0.268 
 Penn-NJ 58 251 247 0.330  31 151 165 0.307  1.11 (0.96, 1.29) 0.306 
 Oregon 60 252 197 0.365  26 117 110 0.334  1.15 (0.98, 1.34) 0.227 
 Spain(IDIS-Sgo) 33 145 170 0.303  22 107 147 0.274  1.15 (0.97, 1.37) 0.252 
 Massachusetts E.E. I. ** 45 178 163 0.347  17 87 86 0.318  1.14 (0.95, 1.37) 0.332 
 Case Western Reserve -- -- -- --  -- -- -- --  -- -- 
 Pittsburgh ** 24 77 69 0.368  18 55 70 0.318  1.25 (0.99, 1.58) 0.940 
 Miami/Duke/Vanderbilt ** -- -- -- --  -- -- -- --  -- -- 
              
  Japan 31 228 395 0.222   17 80 236 0.171   1.39 (1.17, 1.65) 0.008 
             
 Test of heterogeneity:      Q  d.f. p.value           
    4.18  6  0.6524                  
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PART 3/3 
rs12678919 (G/A) near LPL 
   Cases    Controls     
    G/G G/A A/A P(G)   G/G G/A A/A P(G)   OR P* 
 Discovery 23 448 1686 0.115  9 206 939 0.097  1.38 (1.17, 1.63) 0.002 
 Tufts/MGH -- -- -- --  -- -- -- --  -- -- 
 Tufts/MGH II -- -- -- --  -- -- -- --  -- -- 
 Johns Hopkins -- -- -- --  -- -- -- --  -- -- 
 Penn-NJ -- -- -- --  -- -- -- --  -- -- 
 Oregon 6 85 416 0.096  2 42 208 0.091  1.06 (0.73, 1.53) 0.783 
 Spain(IDIS-Sgo) 2 81 162 0.173  5 63 149 0.168  1.04 (0.74, 1.46) 0.832 
 Massachusetts. E.E. I. ** -- -- -- --  -- -- -- --  -- -- 
 Case Western Reserve -- -- -- --  -- -- -- --  -- -- 
 Pittsburgh ** 1 32 141 0.098  1 21 127 0.077  1.30 (0.75, 2.27) 0.486 
 Miami/Duke/Vanderbilt ** 5 139 555 0.107  3 40 203 0.093  1.17 (0.83, 1.66) 0.385 
              
  Japan 10 141 496 0.124   6 64 253 0.118   1.06 (0.80, 1.42) 0.668 
             
 Test of heterogeneity:     Q  d.f. p.value             
     0.62 3  0.8926                  
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rs1883025 (G/A) near ABCA1 
   Cases    Controls     
    G/G G/A A/A P(G)   G/G G/A A/A P(G)   OR P* 
 Discovery 1171 845 141 0.739  571 480 99 0.705  1.25 (1.12, 1.40) 0.003 
 Tufts/MGH -- -- -- --  -- -- -- --  -- -- 
 Tufts/MGH II -- -- -- --  -- -- -- --  -- -- 
 Johns Hopkins -- -- -- --  -- -- -- --  -- -- 
 Penn-NJ -- -- -- --  -- -- -- --  -- -- 
 Oregon 299 180 27 0.769  126 111 15 0.720  1.29 (1.01, 1.65) 0.039 
 Spain(IDIS-Sgo) 174 155 17 0.727  143 97 35 0.696  1.16 (0.91, 1.49) 0.238 
 Massachusetts. E.E. I. ** 205 138 42 0.712  98 79 10 0.735  0.89 (0.67, 1.17) 0.405 
 Case Western Reserve 713 418 67 0.770  821 563 77 0.755  1.09 (0.96, 1.23) 0.270 
 Pittsburgh ** 104 66 7 0.774  89 45 12 0.764  1.06 (0.73, 1.53) 0.318 
 Miami/Duke/Vanderbilt ** 378 275 47 0.736  130 98 20 0.722  1.08 (0.86, 1.36) 0.858 
              
  Japan -- -- -- --   -- -- -- --   -- -- 
             
 Test of heterogeneity:     Q  d.f. p.value              
    4.25 5 0.5137                 
 
** Note that for datasets that include related individuals (Pittsburgh, Miami/Due/Vanderbilt and Massachusetts. E.E. I.), this samples counts include only unrelated individuals. 
Thus, the results differ from those in Table 3 in the main paper where all available samples were analyzed using the method of Thornton and McPeek. The tabulated p-values are 
calculated from the complete family data set. P values are two sided.  
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Table 2.8 Best genotyped proxy SNPs for reported loci 
SNP Chrom Position Gene P-value at Imputed SNP 
Best 
Genotyped 
Proxy 
Allele1/ 
Allele2 
 Cases 
1/1 1/2 2/2 
Controls 
1/1 1/2 2/2 Rsq 
P-value at 
Genotyped 
SNP* 
rs10737680 1 194,946,078 CFH 1.6 × 10-76 rs1329428 A/G  86/685/1384 214/571/365 1.00 5.2 × 10-76 
rs3793917 10 124,209,265 ARMS2/HTRA1 4.1 × 10-60 rs6585827 G/A  377/993/782 335/557/256 0.32 7.5 × 10-22 
rs429608 6 32,038,441 C2/CFB 2.5 × 10-21 rs429608 A/G  18/311/1827 27/311/812 1.00 2.5 × 10-21 
rs2230199 19 6,669,387 C3 1.0 × 10-10 rs2250656 G/A  139/775/1243 107/491/552 0.08 1.3 × 10-7 
rs2285714 4 110,858,259 CFI 3.4 × 10-7 rs2285714 T/C  462/1076/617 187/534/429 1.00 3.4 × 10-7 
            
rs1329424 1 194,912,799 CFH 6.4 × 10-16 rs2019724 G/A  271/998/886 432/546/172 0.79  1.3 × 10-14 
rs9380272 6 32,013,989 C2/CFB 2.3 × 10-8 rs9332702 G/C  0/67/2089 0/27/1123 0.50 1.1 × 10-7 
            
rs9621532 22 31,414,511 SYN3/TIMP3 3.9 × 10-5 rs135150 C/T  45/519/1592 32/330/787 0.14 0.001 
rs493258 15 56,475,172 LIPC 2.1 × 10-3 rs1532085 A/G  255/949/951 179/509/462 0.64 0.002 
rs3764261 16 55,550,825 CETP 1.4 × 10-6 rs3764261 T/G  296/979/882 118/485/546 1.00 1.4 × 10-6 
   
*The second cluster is conditional on the five SNPs in the first cluster. The third cluster is conditional on the 7 SNPs above. Marginally, the SNPs in second 
cluster are not significant.   
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Table 2.9 Association Results in Discovery Sample for Different Analysis Models 
  Analysis Covariates 
SNP 
Notable Nearby 
Genes None 
Principal Components 
of Ancestry (PCA) 
PCA and Index SNPs 
at Previous  Loci 
PCA, Previous Loci 
Age and Sex 
rs10737680 CFH 2.5 × 10-78 1.6 × 10-76 -- -- 
rs3793917 ARMS2 1.7 × 10-60 4.1 × 10-60 -- -- 
rs429608 C2/CFB 4.7 × 10-21 2.5 × 10-21 -- -- 
rs2230199 C3 3.6 × 10-11 1.0 × 10-10 -- -- 
rs2285714 CFI 8.0 × 10-8 3.4 × 10-7 -- -- 
rs9621532 TIMP3 5.9 × 10-5 2.6 × 10-4 4.5 × 10-5 7.1 × 10-4 
rs493258 LIPC 5.1 × 10-3 6.9 × 10-3 3.6 × 10-3 1.1 × 10-2 
rs3764261 CETP 5.8 × 10-5 1.2 × 10-4 4.6 × 10-6 9.5 × 10-6 
rs12678919 LPL 1.7 × 10-2 2.0 × 10-2 4.0 × 10-3 2.9 × 10-3 
rs1883025 ABCA1 3.4 × 10-3 6.4 × 10-3 5.2 × 10-3 4.9 × 10-3 
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Table 2.10 Evaluation of Association of Loci with p < 5x10-8 Overall In Specific AMD Subtypes (OR, 95 C.I., p-value) 
 
 
rs10737680 
(CFH)  
rs3793917 
(ARMS2)  
rs429608 
(C2/CFB)  
rs2230199 
(C3)  
 
rs2285714 
(CFI) 
  
rs9621532 
(TIMP3) 
 
Alleles 
(A/C)  
Alleles 
(G/C)  Alleles (G/A)  
Alleles 
(C/G)  
Alleles 
(T/C) 
 Alleles 
(T/C) 
            
Large Drusen  (529) vs Control (1150)  
2.69  
(2.27,3.20)  
2.36 
 (1.94,2.87)  
2.03  
(1.59,2.59)  
       1.66  
(1.32,2.08)  
1.26  
(1.08,1.45) 
 1.47  
(1.03,2.12) 
 2.2 × 10-29  4.4 × 10-26  1.8 × 10-8  1.2 × 10-5  2.3 × 10-3  0.03 
            
GA   (465) vs Control (1150)  
3.85  
(3.15,4.71)  
3.68 
 (3.07,4.42)  
2.46  
(1.95,3.10)  
2.00  
(1.62,2.46)  
1.38  
(1.21,1.57) 
 1.31  
(0.91,1.88) 
 1.0 × 10-39  1.7 × 10-44  2.0 × 10-14    6.3 × 10-11  1.4 × 10-6  0.14 
            
Neovascular (1163) vs Control (1150)  
3.15  
(2.73,3.63)  
4.28 
 (3.63,5.04)  
2.16  
(1.79,2.61)  
1.67  
(1.38,2.00)  
1.34  
(1.19,1.50) 
 1.91  
(1.42,1.91) 
 1.4 × 10-57  1.1 × 10-66  1.3 × 10-15  7.9 × 10-8  1.3 × 10-6  1.9 × 10-5 
            
GA  (465) vs Large Drusen (529)  
1.38  
(1.11,1.73)  
1.26  
(1.02,1.55)  
1.12  
(0.81,1.55)  
1.22  
(0.93,1.60)  
1.09  
(0.91,1.30) 
 1.12  
(0.72,1.73) 
 4.3 × 10-3  0.032  0.48  0.15  0.36  0.62 
            
Neovascular (1163) vs Large Drusen 
(529)  
1.13  
(0.95,1.35)  
1.79  
(1.50,2.13)  
1.07  
(0.83,1.39)  
0.99  
(0.80,1.24)  
1.06  
(0.92,1.23) 
 1.30  
(0.88,1.92) 
 0.16  4.3 × 10-11  0.59  0.95  0.43  0.19 
            
Neovascular  (888) vs GA  (465)  
0.76  
(0.61,0.93)  
1.36  
(1.13,1.63)  
0.90  
(0.67,1.20)  
0.78  
(0.62,1.00)  
0.95  
(0.81,1.12) 
 1.39  
(0.93,1.39) 
 0.009  0.0009  0.47  0.046  0.54  0.11 
 
The entry corresponding to the largest odds ratio in each column is bolded. 
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Figure 2.1 Summary of genomewide association scan results  
 
The top panel summarizes the significance of the association signal at each examined SNP in the discovery samples. 
The five known loci are highlighted in green. The three strongest loci after follow (TIMP3, LIPC, CETP) are 
highlighted in blue. The bottom panel displays a quantile-quantile plot for test statistics. The shaded region in the 
bottom panel corresponds to a 90% confidence interval for the test statistics. 
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Figure 2.2  Regional plots for association signals in five previously reported loci 
 
 
Detailed plots of association in the discovery samples in five confirmed regions (CFH, ARMS, C2/CFB, C3 and CFI) 
are shown. The most significant SNP in each region is highlighted in a red square and other SNPs are drawn as colored 
circles reflecting linkage disequilibrium (LD) with the top selected SNP. Exons and transcript direction for genes in 
each region are indicated in bottom panel.  
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Figure 2.3 Regional plot for association signals in the three new loci 
 
                      
 
Detail plots for the regions surrounding the SYN3/TIMP3, LIPC and CETP regions. Original, follow-up, and combined 
p-values for the SNP selected for replication are indicated on the left. Discovery sample p-values for the index SNP and 
other nearby SNPs are plotted.  
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Figure 2.4 Regional plot of association signals in HDL-c and AMD 
 
 
Detailed plots comparing HDL-cholesterol association signals (from the discovery sample of Kathiresan et al27; left 
column) and AMD association signals (from the discovery sample in the scan reported here; right column). The same 
marker and linkage disequilibrium proxies are highlighted in each row. 
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Figure 2.5 Multi-locus genotypes and disease risk 
 
 
 
 
 
The top panel summarizes the proportion of affected individuals in each risk decile, with the highest risk decile on the 
left, when our sample is segregated according to the risk of disease predicted by a simple logistic regression model.  
The bottom panel makes equivalent predictions at the population level, after weighting cases and controls to take into 
account that our sample is enriched for cases (see methods for details). 
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Chapter 3  
Graphical Browser for GWAS with High-dimensional Phenotypes 
 
 
The content of this chapter has been published in Chen et al. 2009 [59]. 
 
3.1 Introduction 
 
Recently, genome wide association scans (GWAS) have been used to successfully dissect 
a variety of complex traits, ranging from discrete clinical outcomes such as asthma and 
diabetes [60-62] to continuous traits as diverse as height, weight, global gene expression 
and blood lipid levels [63, 64]. The amount of information generated in these studies is 
staggering and interpreting their results requires efficient computational tools for data 
analysis and visualization. This challenge is most noticeable when high-dimensional data 
(such as microarray gene expression data or proteomics data) is analyzed. In this case, the 
results of whole genome association studies can include billions of data points [63, 65]. 
Realizing the full benefits of these studies requires an efficient way to share data among 
collaborators and with other researchers, both before and after the data is published. Here, 
I present a tool that facilitates interactive browsing of the results from whole genome 
association studies. To illustrate the capabilities of our browser, I used it to create an 
interactive interface for the results of a recent genome-wide association study of global 
gene expression. The objective of the Dixon et al (2007) study was to build a database 
that would allow researchers to systematically examine potential effects of disease-
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associated variants on transcript expression and our interactive browser makes it easy for 
many researchers to explore the data.  
 
A diverse set of statistical methods can be used to examine the association between 
phenotypes of interest and SNP data. For example, chi-squared test statistics, p-values, 
effect size estimates and their standard errors, as well as SNP specific heritability 
estimates are all commonly reported in GWAS studies. When there are tens of thousands 
of phenotypic outcomes and hundreds of thousands SNPs, the result set is usually very 
large, containing several million statistics and easily totaling several gigabytes. These 
datasets can be integrated into specialized local databases for further investigation, but it 
can be challenging for researchers without extensive database or programming skills to 
access results. Our GWAS GUI (Graphic User Interface) is intended to provide a 
convenient tool for interacting with arbitrary GWAS result sets and to facilitate searches 
and displays of GWAS results in graph or tabular form. I hope our tool will facilitate data 
sharing within collaborative groups and with the public at large. 
 
3.2 Features of GWAS GUI Browser 
 
Our GWAS GUI browser is an interactive package that facilitates rapid interactive 
browsing of whole-genome association study results. It is designed to handle thousands 
of phenotypes, and thus can handle very rich datasets, such as those where global surveys 
of gene expression are combined with genome-wide SNP data. The browser also allows 
users to interact with the results of simpler scans, such as scans that focus on a single 
discrete outcome or a small number of related traits. To evaluate the program, I have 
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applied it to several large datasets, including a study evaluating the association between 
408,273 SNPs and the levels of 54,675 transcripts representing 20,599 known genes and 
assessed in lymphoblastoid cell lines from ~400 children [63]. After this initial evaluation, 
I released an early version of the program, named the mRNA by SNP browser (MRBS), 
when the Dixon et al (2007) paper was published. In addition to the visualization tool, the 
full GWAS GUI browser includes a data preparation tool that can be used to organize 
tabulated results into an indexed database for rapid browsing. There are two main 
browsing interfaces within our browser: (a) an interface that retrieves all results for a 
specific trait and (b) an interface that retrieves all results in a specific genomic region. In 
either view, results can typically be retrieved almost instantaneously. In the “trait-centric” 
view, the browser can tabulate and sort a summary of user provided association test 
results (e.g. effect size, standard error, heritability estimates, test statistics, and p-value) 
and quickly generate plots that summarize the distribution of a user specified test 
statistics along the genome. Alternatively, in the “position-centric” view, the browser can 
tabulate all significant association test statistics (using a user defined threshold) in a 
target region and plot the results for multiple traits. Optionally, information such as the 
location of nearby genes can also be displayed (see Figure 3.1). For convenience, both 
interfaces allow the browser to link the results to external databases chosen by the user, 
such as the University of California Santa Cruz (UCSC) genome browser, where users 
can examine the genomic context of each result in detail. When the user requests a SNP 
that is not included in the current dataset, LD and tag information from the International 
HapMap Consortium can be used to suggest a backup tag-SNP. Figure 3.1 is an 
illustration of the browser interface after searching for a specific SNP position using the 
 44 
 
“position-centric” view. Four SNPs of interest have been highlighted by the user in the 
tabular view (bottom-left) and are circled in the graphical view. 
 
3.3 Examples of Application 
Allowing large groups of scientists to browse and interact with the results of large multi-
dimensional GWAS can be extremely helpful. For example, prior to the publication of 
the Dixon et al. (2007) gene expression paper I used an early version of our browser to 
share preliminary results with several colleagues. This led to the observation that SNPs in 
an intergenic region on chromosome 5p13 that were associated with Crohn's Disease 
were also associated with transcript levels of PTGER4 suggesting that PTGER4 may be 
the primary candidate gene for Crohn’s disease on chromosome 5. The Crohn’s 
associated SNPs are more than 200 Kb away from the nearest annotated gene. The result 
is published and described in detail elsewhere [66]. Since then, many others have 
browsed our results resulting in several potential links between SNPs, human disease, and 
mRNA transcript levels. 
 
The current version of the GWAS GUI browser program is not restricted to gene-
expression data, but is intended as a general tool that provides graphical overviews of 
whole-genome association study results for arbitrary phenotypes. The extended program 
allows users to load their own data files, tests statistics and genomic annotation files into 
the browser in a standardized text format. Generally, the traits can be any outcomes of 
interest, such as case-control indicators, expression values, and many other continuous or 
categorical measurements. Arbitrary meta-data about each trait can be tracked and 
displayed. I expect the browser will be particularly helpful when multiple related traits 
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are studied. In this setting, the browser simplifies the initial comparison of signals for 
different related traits in regions of interest.  
 
3.4 Implementation 
 
The GWAS GUI browser program was implemented in C++ using the Qt4 toolkit (open-
source version 4.3 Trolltech Inc.). It has been tested on Windows, Linux and Mac 
workstations. The system requirements depend on the size of input data sets range which 
can range from a dataset examining a single trait dataset and hundreds of thousands of 
genetic markers to large scale genome wide gene-expression datasets with tens of 
thousands of traits and markers.  On a a modern Windows Workstation, the initial 
indexing of a set of results generated by PLINK [67], MERLIN [68] or another whole 
genome analysis tools and including ~300,000 SNPs requires ~200 MB of RAM and five 
to ten minutes of computing time. After indexing, opening the same dataset and browsing 
the data should be nearly instantaneous and require only 60 MB RAM.   
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Figure 3.1 An illustration of the GWAS GUI browser interface 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This example demonstrates how to display the results for a specific region. The several largest 
statistics are highlighted in blue circles by selecting the corresponding rows. The top transcripts 
ordered by maximum statistics within that region are tabulated in the right panel with 
corresponding genes. 
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Chapter 4  
Genotype Calling and Haplotyping in Parent-Offspring Trios 
 
 
4.1 Introduction 
 
In the past decade, genome-wide association studies (GWAS) have identified 
associations between >1,000 common variants and a variety of complex traits and 
diseases [1, 69]. Next generation sequencing technologies enable researchers to look 
beyond the common variants typically evaluated in genomewide association studies and 
systematically consider the contributions of rarer variation[70, 71]. The ability to 
systematically examine these rare variants may improve our understanding of complex 
traits, by identifying the underlying biological mechanisms more completely and by 
improving our ability to predict individual outcomes[6, 72]. 
 
Next generation sequencing technology can be used to study rare variation either by 
directly sequencing study samples or using genotype imputation approaches to impute 
variants observed in a small number of reference samples into larger sets of phenotyped 
individuals. In the first case, it is of primary importance to obtain accurate genotypes for 
each of the studied individuals. In the second case, it is also important to obtain accurate 
haplotypes for each sequenced individual, since these are a key reagent in the imputation 
based analyses that follow. Since short reads from massively parallel technologies 
typically contain errors, some degree of redundancy is required to ensure adequate 
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estimates of genotypes and haplotypes and sequencing depth is a key variable in 
determining the accuracy of estimated genotypes and haplotypes [14, 73].  
 
Most ongoing sequencing studies have focused on the analysis of unrelated samples. An 
example of the utility of sequencing related individuals is the work of Roach et al[74]. By 
sequencing a nuclear family, including two children with Miller syndrome and their 
parents, Roach et al [74] were able to identify the majority of sequencing errors and 
narrow their search for functional alleles. I reasoned that, by imposing constraints of 
Mendelian inheritance and by ensuring that many rare variants would be observed in 
multiple individuals, sequencing parent-offspring trios would improve genotype and 
haplotype calls, particularly in cases where each individual is sequenced at low depth[75, 
76]. 
 
Here, I describe a new statistical method for estimating individual genotypes and 
haplotypes when next generation sequence data is available on parent-offspring trios. I 
organize this chapter as follows. First, I will describe how a hidden Markov model 
designed for analyses of sequence data in unrelated individuals can be extended to trios 
and parent offspring pairs in a computationally efficient manner. Second, I evaluate the 
model in a variety of simulated datasets – varying sequencing depth, sequencing error 
rates and sample sizes. Third, I evaluate my method in data from the ongoing Sardinia 
sequencing project. Our results show that my method substantially outperforms existing 
approaches that ignore familial relatedness. 
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4.2 Material and Methods 
 
The Pipeline for SNP Discovery and Genotype Calling 
SNP analyses with next generation sequencing data typically start with three key steps: 
read alignment, site discovery and genotype calling. In the first step, sequenced reads are 
mapped to human reference genome[77, 78] and the alignment is refined to calibrate base 
quality scores and account for known insertion-deletion polymorphisms (indels)[79]. 
Next, variant sites are identified by examining each overlapping base position in the 
genome and taking into account a population genetic model (that might describe a prior 
probability of polymorphism for each site, an allele frequency spectrum and a mutation 
spectrum, for example)[77]. Finally, genotypes at each site can be refined using linkage 
disequilibrium information [75, 76]. The complete process is illustrated Figure 4.1.  Each 
step involves many challenges, but here I focus on the last step of genotype calling and 
haplotype phasing. A companion paper discusses the process of SNP discovery using 
family information [80].  
 
Describing Chromosomes as Imperfect Mosaics 
 
Hidden Markov models can be used to describe the haplotypes of each individual as 
imperfect mosaics of other haplotypes in the sample[81]. The approach is commonly 
used for genotype imputation[10, 12, 14] and can be extended to the analysis of short 
read sequence data[75]. In this section, I briefly review how these models can be used to 
model sequence data in unrelated individuals. First, haplotypes for each individual are 
initialized randomly – sampling a genotype consistent with observed read data at each 
position. Then, I iterate over individuals, updating the haplotypes of each individual 
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using a Hidden Markov Model that describes the pair of haplotypes as an imperfect 
mosaic of other haplotypes in the sample. 
 
To describe the model, it is sufficient to specify how haplotypes for one individual can be 
updated conditional on current haplotype estimates for all other individuals. The first step 
is to calculate P(Ri|Gi), the likelihood of observed read data Ri given an hypothetical true 
genotype Gi at each site i. These likelihoods can be pre-calculated conveniently with 
existing tools[82] and can optionally incorporate sophisticated error models, for example, 
to account for correlated errors[77]. Assuming independent errors, a simple definition for 
these likelihoods might be: 
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Here, B and E are vectors of base calls and associated error probabilities for bases 
overlapping position i in the current sample (bj and ej are corresponding elements) and 
I(expression) is an indicator function that returns 1 or 0 depending on whether the 
expression is true or false, respectively. 
The next step, is to define P(Gi|Si), which is the probability of an underlying true 
genotype Gi given mosaic state Si. To calculate this, I use the function T(Si) which returns 
the number of variant alleles in the template haplotypes indexed by Si. Consistent with 
Yun et al[14], I define: 
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iε  denotes the mosaic error rate at i
th marker.   
Together, P(Ri|Gi) and P(Gi|Si) allow us to calculate P(Ri|Si) as: 
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Finally, the last ingredient in the definition of our Hidden Markov Model is to define the 
transition probabilities P(Si+1|Si). 
 
 
 
Here, (x,y) and (w,v) denote indexes for the template haplotypes at position i and i+1 and 
iθ  denotes the mosaic transition rate. 
 
These are all the ingredients needed to calculate P(Si|R), the probability of a specific 
mosaic state at any position along the chromosome. Calculating this probability for all 
possible values of Si allows us to select a pair of ordered alleles for every position (either 
by selecting the most likely pair or by selecting a pair at random, for example). P(Gi|R) 
can be obtained by the formula )|()|()|(
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calculated using Baum’s forward/backward algorithm[83]. Thus, I first define recursive 
left and right probability functions.  
 
The left probability function function Li+1 is defined as: 
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At the first variant site, the function is defined as 
 =(w,v))P(S=(w,v))|SR=(w,v))=P(,S(w,v)=P(RL 111111 × , where P(S1 = (w,v)) is typically assumed to 
be a constant. 
The right probability Qi+1(w,v) function is defined as: 
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At the last variant site M, the function is defined as 1(w,v)=QM  for convenience.  
Finally, I have ),(),()),,(()|),(( vwQvwLRvwSPRvwSP iiii ×==∝= . 
 
Joint Modeling for Trios 
The approach described in the previous section assumes all individuals are unrelated. If 
related individuals are sequenced, the method ignores important constraints on individual 
genotypes and haplotypes imposed by Mendel’s laws. In this section, I propose a strategy 
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for computationally efficient modeling of linkage disequilibrium and Mendelian 
inheritance constraints.  
 
I denote Rf, Rm and Rc as the read data for the father, mother and child in a parent-
offspring trio and the corresponding genotype likelihoods are P(Rf|Gf),  P(Rm|Gm) and 
P(Rc|Gc). In principle, I could extend the previous algorithm, which is designed to sample 
pairs of haplotypes in unrelated individuals, to sample four haplotypes at a time in trio 
parents. The main weakness of this extended model would be that it requires jointly 
iterating over 4 possible haplotypes, resulting in a substantial increase in computational 
burden (compute costs would be proportional to H4 instead of H2, where H is the number 
of haplotypes used for each update). Instead, I use an approximate but computationally 
tractable solution. First, I sample an ordered pair of template haplotypes and an ordered 
genotype for one of the trio parents conditional on the observed read data for the trio. 
Next, I sample an ordered pair of template haplotypes and an ordered genotype for the 
second parent conditional on observed read data and the sampled haplotypes for the first 
parent. For convenience, I assume the first allele in each ordered haplotype is transmitted 
to the child. In each iteration, the order in which parents are updated alternates randomly. 
 
Let ),,( )()()( icimifi RRRR =

denotes available read information for the father, mother and 
child at position i. When sampling the first parent, I now replace equation 1 with : 
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Updates for the second parent, condition on the sampled genotype for the first parent in 
addition to read data and replace equation 1 with: 
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To calculate the first quantity, I use: 
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Where the transmit function transmit(Gf,Gm) returns the child haplotypes implied by the 
ordered parental genotypes Gf and Gm. 
 
To calculate ),|( mii GSRP

, I note that
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When dealing with samples that include trios, our algorithm proceeds as follows:  
a) Find an initial set of haplotypes that is consistent with available read data (see 
Appendix A). 
b) Sample a new pair of template haplotypes and corresponding genotypes for 
each unrelated individual. 
c) For each nuclear family, randomly pick one parent and sample a new pair of 
haplotypes for that parent. Then, sample a new pair of haplotypes for the other 
parent conditioning on both observed read data and the previous  pair of 
sampled haplotypes. 
d) Record sampled haplotypes for every individual 
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e) Update estimated recombination and error rates. 
f) Repeat steps b through e). 
 
Generating Consensus Haplotypes 
Each round of updates generates a new pair of haplotypes for each sequenced individual. 
After a pre-defined number of rounds, a pair of consensus haplotypes for each unrelated 
individual is generated by finding the haplotype pair that minimizes switch error in 
relation to sampled haplotypes[14, 75]. For parent-offspring trios, where sampled 
haplotypes are ordered I don’t attempt to minimize switch error and simply assign each 
consensus haplotype the most frequently sampled allele at that position. 
 
4.3 Data Sets 
Simulated Data 
 
To evaluate the performance of our method, I start with simulated data sets, which mimic 
the real shotgun sequencing output. The advantage of simulated data is that I can have 
comprehensive evaluations by setting up different scenarios and assessing a wide range 
of possibilities in real studies. In addition, I can compare the results to truth, which is 
usually unknown for real studies. To be realistic, I simulated 10,000 haplotypes for 
multiple 1 Mb regions using a coalescent model mimicking realistic LD patterns, 
modeling  population demographic history and local recombination rates similar to 
European ancestry[84].  Next, I randomly selected haplotypes for founders and generated 
haplotypes of offspring by family inheritance information.  At each site, read depths 
followed a Poisson distribution and each base was simulated according to a specified per-
base error rate.  Finally, genotype likelihoods P(R|Gi) were calculated based on the 
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simulated reads R. More details and implemented software are described in the 
companion paper[80]. 
 
I simulated 30 trios, 60 and 90 unrelated samples at depth 1X, 2X, 4X and 8X with per-
base error rate 0.01 (Q20) or 0.001 (Q30).  Then I doubled the sample size to 60 trios, 
120 and 180 unrelated samples. Recall that depth is defined as the average number of 
read covering each site. I repeated the simulation 100 times. 
 
Real Data 
I applied this method to ongoing Sardinia sequencing projects. Up to 2,000 Sardinia 
samples are being sequenced at an average depth of 3.7X at the University of Michigan. 
The pilot study consists of complete trios, parent-offspring pairs and unrelated samples 
(Table 4.3). Most of the samples are also genotyped in Metabo-Chip with high accuracy. 
It’s a perfect data set to evaluate the performance of our method in that I can compare the 
called genotypes to those sites also genotyped in the Metabo Chip. I focused on two 
recently generated data sets with sample size and structure listed in Table 4.3. I compared 
our genotype calling results to the Metabo Chip at overlapping samples and sites. In 
addition, I also applied two other methods - a) LD-based method ignoring relatedness and 
b) single marker caller developed in the companion paper - for comparisons. 
  
Metrics of Performance 
 
To have comprehensive evaluation of the algorithm, I defined a number of metrics to 
quantify the performance of the genotype calling and phasing results. 
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Genotype calling: 
1. Overall genotype mismatch rate – the percentage of incorrectly called genotypes 
2. Mismatch rate at true heterozygous sites – the percentage of incorrectly called 
heterozygous genotypes 
 
Since the frequency affects above quantities substantially, I stratified the results 
according to population frequency spectrums. 
 
Haplotype phasing: 
 
1. Mismatched genotypes – the number of mismatched genotypes between inferred  
and true haplotypes in the simulated region 
2. Flips - the number of switch errors between inferred and true haplotypes 
excluding mismatched genotypes 
3. Perfectly predicted haplotypes – the number of inferred haplotypes without any 
flip excluding mismatched sites. The quantity is expected to be smaller when the  
region is enlarged. It will also depend on the number of mismatched sites. 
However, if the numbers of flips and mismatched sites in method A are both less 
than method B,  method A is clearly superior to B in terms of phasing accuracy. 
 
 
4.4 Results 
 
Overall Performance 
I evaluated the performance of the methods on the simulated and real sequencing data 
sets. I will show the relative performance pattern of different study designs. The absolute 
numbers are only specific to the current sample size, parameters used in simulation and 
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methods performed. Given the various parameters, I will only discuss some examples in 
the table for general patterns.   
 
As shown in Table 4.1, comparing 30 or 60 trios with 60 or 120 unrelated samples, 
sequencing an additional child can always detect more variants, as expected. For the 
same sequencing cost, comparing 30 trios or 60 trios with 90 or 180 unrelated samples, I 
could detect more variants for trios at low depth (1X and 2X) but unrelated samples can 
outperform trios at 8X in terms of genotyping accuracy. Both are comparable at 4X. The 
sequencing base error rate also affects the SNP discovery.  Generally, I can call 10% 
more SNPs when base error rate is reduced from 0.01 to 0.001.  
 
Henceforth, I will focus on evaluating the mismatch rates. For each sample category, the 
mismatch rate decreases as the depth increases and heterozygote sites grow more difficult 
to infer. Increasing the sample size could result much improvement. For example, at base 
error rate 0.01 and 2X coverage, the mismatch rate of 120 unrelated samples is 2.7% 
compared to 4.4% of 60 unrelated samples. The elevated sequencing error caused by 
multiple reasons also challenges the genotype calling. The observation in Table 4.1 
indicates that the mismatch rate increases as the base error rate increases, but the impact 
is not big relative to the sample size and the depth. For instance, with the base error rate 
1% and 1X, the mismatch rate of 30 trios is only 4.5% compared to 3.8% with the error 
rate 0.1%. Considering that the base error rate in current sequencing technologies is 
expected to lie between 0.001 and 0.01, increasing sample size and sequencing depth will 
more efficiently increase the genotype calling accuracy. Next, I compare the performance 
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of trios to unrelated samples. For each set of comparisons, I compared trios to two sample 
sizes of unrelated samples, which correspond to the same number of independent samples 
and same sequencing cost as the trios. Generally, sequencing trios has lower mismatch 
rates at all sites and heterozygote sites for all categories. For instance, the mismatch rate 
of 30 trios at depth of 2X with error rate 0.001 is 1.1% compared to 2.4% and 3.2% for 
60 and 90 unrelated samples. The gain at high depth of coverage (8X) is still remarkable, 
even though the genotypes can be inferred confidently from its own genotype likelihood 
based on the single marker. 
 
Although I called genotypes for both parents and child jointly, mismatch rates are still 
slightly differences between them especially at high depth (Table 4.7). For example, the 
mismatch rate of child is 0.3%, comparing to 0.45% at the depth of 4X and error rate 
0.01. It is expected in the reason that the two chromosomes of the child are actually 
double sequenced.  
 
Performance by Stratified Frequency 
The number of discovered SNP is always limited by the sample size. Given the sample 
size in the simulation, the evaluation of the method might be biased towards common 
variants since rare variants are difficult to discover before the genotype calling steps. 
Therefore, to have more comprehensive evaluations, I carried out the analysis on 
different allele frequency categories. More specifically, I categorized all SNPs into 10 
even frequency bins. The frequency refers to the base allele in the reference genome. 
Examining only heterozygous sites can provide a more accurate evaluation of the method 
 60 
 
especially at rare variants. I will only focus the heterozygous sites. An evident pattern is 
shown in Figure 4.3 with 30 trios, 60 and 90 unrelated samples at 2X. The figures for 
other scenarios are very similar. Table 4.7 gives detailed information. The top panel is the 
overall mismatch rate at different depths. Sequencing more samples can yield a lower 
mismatch rate. 30 trios outperform 60 and 120 unrelated samples in all frequency 
categories at all depths. However, the absolute gain is marginal at 8X since all mismatch 
rates are already very slow.  For low frequency categories, the major allele homozygotes 
dominate the performance, but the heterozygous sites are more difficult to infer. As I can 
see, the relative order of performance is unchanged. Trios are even more beneficial at 
heterozygous sites for low frequency categories. This behavior is expected because 
although a rare variant is not easy to sample from reference panel, it is actually double 
sequenced if it passes to offspring, which increases the likelihood of correctly inferring 
heterozygotes. 
 
Accuracy of Haplotype Inference 
Another important result of our method is the haplotype reconstruction, which is essential 
for follow-up imputation and population history inference. I evaluate the accuracy of our 
method by comparing three quantities jointly as defined in our method part: errors, flips 
and perfectly predicted haplotypes. I show the simulation results in Table 4.2. The region 
is 1 Mb long and the number of compared sites depends on each sample size. As 
expected from GWAS, a larger sample size can always increase phasing accuracy. For 
instance, at 4X, 90 unrelated samples yield 40 flips, while 60 unrelated samples have 60 
flips. Trios have great advantage in haplotype inference. 30 trios only have 2 flips at 4X. 
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It is important to recall that mismatched sites were excluded from the haplotypes to 
calculate the flips. A better phasing method needs to have both lower mismatch rate and 
number of flips. The number of perfectly predicted haplotypes is not comparable for 
different depths, but the relative pattern reveals that trios have a great advantage in 
haplotype inference. 
 
Performance on Sardinia Sequencing Data 
The performance of our method in simulation data sets is encouraging. However, it has 
always depended on simulation models. Clear performance pattern could be 
demonstrated with a realistic model. It is more interesting to see what happens in real 
data sets. As described in the method part, three approaches were used to call genotypes. 
I summarized the comparison results at the available genotypes on chromosome 20 in 
Metabo Chip in Table 4.4. I present genotype mismatch rate on both overall and 
heterozygote sites and further stratify the results into different categories by minor allele 
frequency. I will focus on heterozygous sites. The general message is that heterozygous 
sites are more difficult to infer for all methods. For LD-based algorithm, the large sample 
size yields better genotype calling accuracy; the single marker caller variant sites. For 
instance, a single marker approach has high overall mismatch rate of 11.4% compared to 
2.4% for the LD-based approach ignoring relatedness and 1.5% for our approach.  Our 
approach outperforms the LD-based algorithm ignoring relatedness in all categories, 
reducing the mismatch rate from 4.2% to 2.4 % for the first data set and 2.4% to 1.6% for 
the second data set. Table 4.5 presents the stratified results. LD-aware method performs 
much better at common sites. At rare variants sites, more samples are needed. For 186-
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sample data set, our method has best performance in all categories. Although our 
methods are promising, the limited counts and accuracy of Metabo chip at rare sites 
require more investigation when more data are generated. 
 
Summary 
Our simulations show that sequencing trios can have similar or even higher variant 
calling rates at both all and heterozygote sites compared to the same number of unrelated 
individuals at low depth 1X and 2X.  For depths of 4X and 8X, although sequencing 
unrelated samples has more power to detect variants, sequencing trios have the advantage 
of higher sensitivities at heterozygous sites, which is crucial for individual genotype call 
of rare variants. As the sample size increases, I expect sequencing trios will have 
increased advantages. Generally, sequencing trios has the higher calling accuracy across 
different frequency spectrums. In addition, trios can greatly increase the haplotyping 
accuracy. Applying our method to Sardinia sequencing project leads to better genotype 
calling accuracy than an approach that ignores the relatedness. 
 
Computational Complexity 
 
Since our state space is ungrouped and in the square of the number of reference 
haplotypes, the complexity of the LD-based approach for SNP calling is O(N3), which 
increases rapidly as N increases. Sampling from the joint space of two parents will make 
the computation infeasible in practice. Calculating the marginal emission probabilities 
conditional on alternatively sampled parent keeps the same scale of computation as 
unrelated cases but incorporates the trio information simultaneously. Our approach also 
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orders the genotypes so that the genotypes of the offspring are determined by the 
genotypes of the parents. This could reduce the size of reference panel and save 
computing time if there is big proportion of trios in the study. 
 
 
4.5 Discussion 
 
The new method this paper presents can accurately call genotypes and infer haplotypes 
for shotgun sequencing data. It can handle unrelated samples and parent-offspring pairs 
in a manner similar to common LD-based approaches for genotype calling and 
imputation of unrelated individuals. The family information is simultaneously taken into 
account in the hidden Markov model. This method can be used in many pipelines for 
shotgun sequencing data. In the sequencing project, once a set of polymorphic sites are 
called (e.g. family-based approach presented in the companion paper), our method can 
refine individual genotypes. The output of our program has both inferred genotypes and 
posterior probabilities, which could be used selectively in follow-up association tests.  
 
SNP genotype imputation method has been widely used in GWAS and benefits many 
large scale meta-analyses [4, 38]. Some comprehensive evaluations of different 
imputation methods have been published [8, 85].  A common conclusion is that a LD-
based algorithm performs well in common variants but has limitations in uncommon or 
rare variants. The main reason is that rare variants occur less frequently in study samples; 
LD information may often “correct” true rare heterozygous sites into homozygotes.  A 
similar issue has appeared, although not comprehensively, in our simulation studies for 
shotgun sequencing in unrelated samples. Inheritance information from offspring can 
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increase the likelihood of correctly inferring rare heterozygotes and avoid miscorrection 
by LD information from the population. I expect adding more family members will 
continuously improve genotype calling accuracy for rare variants. Furthermore, if the trio 
based design finds interesting rare variants in a region to be associated with some disease 
through the trio based design, I can sequence more family members, if available, and use 
the family-based caller[80] to confirm those rare genotypes. This two-step approach will 
eliminate the false positives more efficiently and increase power to detect true causal 
variants. 
 
One big advantage of LD-aware caller is haplotype inference or phasing, which is not 
available from single marker based caller. Haplotype inference is crucial in follow-up 
studies such as haplotype association analysis or estimation of r2 to assess the LD blocks. 
If all samples are unrelated, then the sampled haplotypes are basically copies of different 
mosaics of reference haplotypes in the population. Trio data sets impose the family 
constraints and guide the sampling steps in Markov model. More beneficially, samples in 
many ongoing sequencing projects are often a small portion of existing GWAS. Those 
sequenced samples serve as the reference panel to impute the polymorphic sites detected 
in the unsequenced samples in GWAS. Accurate phase information will benefit the 
imputation step and greatly reduce computational cost. . 
 
I proposed two approaches for initial guess of haplotypes. I showed that our method 
achieved better accuracy than the single marker caller and the method that ignores the 
relatedness with a random initial guess of the haplotypes. In practice, I can even do better 
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using the haplotypes inferred from other software. For example, I used the haplotypes 
inferred from BEAGLE as starting point of our method on a latest released data set with 
508 samples. From Table 4.6, even after 30 rounds, our method can reach very low 
mismatch rate (0.49% at all sites, 1.04% at heterozygous sites).    
 
The main focus of this paper is to evaluate the performance of our method in terms of 
accuracy of genotype calling and haplotype inference. Although sequencing trios can 
increase the accuracy of both genotype calling and haplotype inference, it does not imply 
that the design of sequencing trios is more preferable to unrelated samples with the fixed 
total sequencing cost. Sequencing more unrelated samples may have more power in SNP 
discovery[80] and follow-up association tests. This question is beyond the scope of this 
paper and deserves further investigation. 
 
Although I have investigated various scenarios, many other interesting experimental 
setups do exist. For example, our simulation fixed the error rate for all bases and depths 
across all samples for each case. It might also be interesting to see what would happen if 
the base error rate varies following some realistic distribution or if offspring has more 
and less depths than parents. Some optimal design may lead to larger power given the 
total sequencing cost or other constraints. 
 
The current approach could be potentially extended to the nuclear family: two parents 
with multiple offspring and general pedigree. A simple starting point might be splitting a 
nuclear family into multiple trios with duplicated parents, updating parents alternatively 
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and summarizing the results across all split trios. A more complicated approach based on 
pedigree likelihood calculation is also possible but I need to recall that the computing 
complexity should be feasible given current computing power. Some approximation or 
genotype space reduction might be useful to speed up the calculation. Parallel computing 
and multiple threading techniques provide a potential solution in practice.  
 
Web Resources 
The URLs for data presented herein are as follows: 
Triocaller: The C++ program based on the method described in this paper, 
www.sph.umich.edu/csg/weich/software/TrioCaller 
Simulator:  www.sph.umich.edu/csg/binghsan 
 
Variant Calling: www.sph.umich.edu/csg/bingshan 
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Table 4.1 Error rates for genotype calling  
 
                 
         Mismatch Rate    
Base   Called Variants    All Sites   Heterozygous Sites  
Error Sample  1X 2X 4X 8X  1X 2X 4X 8X  1X 2X 4X 8X 
0.01 60 unrelated  2112 2548 3079 3757  .1040 .0438 .0120 .0021  .1563 .0563 .0147 .0033 
 90 unrelated  2323 2778 3350 4178  .0809 .0324 .0092 .0016  .1262 .0424 .0112 .0024 
 30 trios  2351 2827 3435 3993  .0380 .0151 .0040 .0008  .0523 .0175 .0048 .0011 
                 
0.001 60 unrelated  2448 2853 3447 4084  .0878 .0319 .0084 .0015  .1774 .0538 .0126 .0030 
 90 unrelated  2616 3128 3796 4576  .0667 .0238 .0065 .0011  .1363 .0405 .0098 .0022 
 30 trios  2641 3172 3773 4223  .0320 .0106 .0031 .0006  .0607 .0169 .0046 .0011 
                 
0.01 120 unrelated  2472 2923 3565 4529  .0687 .0265 .0076 .0013  .1087 .0344 .0093 .0021 
 180 unrelated  2686 3156 3898 5041  .0537 .0203 .0060 .0011  .0863 .0266 .0075 .0016 
 60 trios  2722 3253 4049 4866  .0264 .0104 .0027 .0005  .0371 .0120 .0033 .0008 
                 
0.001 120 unrelated  2780 3323 4063 4962  .0559 .0193 .0054 .0009  .1167 .0332 .0082 .0018 
 180 unrelated  3034 3610 4516 5626  .0426 .0146 .0044 .0007  .0917 .0255 .0068 .0014 
 60 trios  3081 3708 4530 5155  .0205 .0070 .0020 .0004  .0404 .0114 .0032 .0007 
                 
                 Error rates for genotype calling in samples of parent-offspring trios or unrelated individuals, as function of sequencing depth (1X, 2X, 4X or 8X) and per base 
error rate of the original sequence traces (0.01 or 0.001)
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Table 4.2 Quality of estimated haplotypes in simulated 1Mb regions 
                
Depth  1X    2X    4X    8X  
 Errora Flipsb Perfectc  Error Flips Perfect  Error Flips Perfect  Error Flips Perfect 
60 unrelated 220.2 46.9 0.2  111.7 58.5 0.3  37.1 59.9 0.4  7.8 60.8 0.2 
90 unrelated 188.7 33.4 0.3  90.0 39.5 1.2  31.0 39.5 2.4  6.6 42.0 0.6 
30 trios 89.5 6.0 6.9  42.8 2.8 26.6  13.8 1.5 47.0  3.2 0.7 68.3 
                
120 unrelated 170.2 26.1 0.6  77.5 28.6 3.1  27.1 30.4 5.4  6.0 33.6 1.8 
180 unrelated 144.4 17.5 2.0  64.1 18.6 12.5  23.4 20.5 14.9  5.4 23.7 6.2 
60 trios 71.9 3.4 36.8  33.6 1.5 88.2  10.8 0.9 118.5  2.6 0.4 150.0 
                
 
a Error: the number of mismatched genotypes per person between inferred and true haplotypes in the simulated region 
b Flips: number of switch errors per person between inferred and true haplotypes excluding mismatched genotypes 
c Perfect: the number of predicted haplotypes with no flips excluding mismatched sites
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Table 4.3 Family structures of the SardiNIA data sets 
   
 Data Set 1 Data Set 2 
Unrelated samples 7 66 
Complete Trio 13 25 
1 Parent with 1 offspring 4 0 
1 Parent with 2 offspring 4 15 
Total 66 186 
Samples genotyped 55 105 
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Table 4.4  Overall genotype concordance between metabochip and low-pass sequence data from Sardinia project 
                    
 
 66 Samples 
 
186 Samples 
 
Count Singlea(%) Thunderb(%) TrioCaller(%) 
 
Count Single(%) Thunder(%) TrioCaller(%) 
Overall  107165 12.70 4.23 2.32 
 
222049 12.18 2.37 1.51 
Heterozygote  31339 28.79 8.69 5.19 
 
60878 28.72 5.53 3.66 
Alternative Homozygote  19412 12.09 3.18 1.59 
 
37307 13.07 1.94 1.23 
Reference Homozygote 56414 3.95 2.12 0.98 
 
123864 3.9 0.96 0.55 
           
a Single is a family-based genotype calling algorithm on single marker. 
b Thunder is a LD-aware genotype calling algorithm ignoring the relatedness. 
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Table 4.5 Stratified genotype concordance between metabochip and low-pass sequence data from Sardinia project 
 
                    
MAFa Nsampleb NSNP Overall (%)    
  
Heterozygots (%)  
      Single Thunder Triocaller 
 
Single Thunder Triocaller 
66 Samples 
         All freq 55 1950 12.70 4.23 2.40 
 
28.79 8.69 5.19 
          0 - 2% 55 75 1.92 2.64 2.32 
 
30.82 16.78 16.08 
2% - 5% 55 180 2.42 2.37 0.91 
 
25.19 11.95 6.30 
> 5% 55 1695 14.26 4.50 2.48 
 
28.87 8.57 5.11 
          186 Samples 
         All freq 105 2116 12.18 2.41 1.55 
 
28.72 5.46 3.66 
          0 - 2% 105 120 1.34 1.42 1.09 
 
34.43 14.47 13.84 
2% - 5% 105 273 2.76 1.34 0.72 
 
34.98 9.53 5.47 
> 5% 105 1723 14.52 2.65 1.71   28.49 5.28 3.51 
           
a MAF denotes the minor allele frequency, stratified in three categories. 
b Nsample is the number of samples with genotypes available in Metabo chip. 
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Table 4.6  Improvement of genotype accuracy with phased input from Beagle 
 
 
                  
MAF NSNP Overall Mismatch Rate (%) 
 
Heterzygotes Mismatch Rate (%) 
    Count Beagle only Beagle+Triocaller   Count Beagle only Beagle+Triocaller 
all 2491 393346 0.68 0.49 
 
102297 1.67 1.04 
         0 - 2% 233 36806 0.22 0.16 
 
696 7.76 4.83 
2% - 5% 328 51797 0.29 0.33 
 
3233 2.88 1.69 
> 5% 1930 304743 0.80 0.55   98368 1.59 0.99 
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Table 4.7 Error rates stratified by frequency at heterozygotes for genotype calling  
 
Reference 
Allele 0-.1 .1-.2 .2-.3 .3-.4 .4-.5 .5-.6 .6-.7 .7-.8 .8-.9 .9-1 
           1X 
          60 unrelated .3076 .2005 .1444 .1226 .1137 .1187 .1259 .1551 .2164 .2630 
90 unrelated .2814 .1597 .1036 .0913 .0874 .0903 .0915 .1115 .1754 .2569 
30 trios .1492 .0484 .0368 .0373 .0378 .0394 .0411 .0461 .0677 .1160 
2X 
          60 unrelated .1299 .0657 .0479 .0423 .0394 .0407 .0406 .0484 .0704 .1122 
90 unrelated .0988 .0452 .0339 .0302 .0290 .0287 .0285 .0327 .0480 .0979 
30 trios .0556 .0160 .0130 .0130 .0130 .0130 .0128 .0144 .0187 .0368 
4X 
          60 unrelated .0435 .0131 .0108 .0105 .0099 .0098 .0100 .0114 .0155 .0329 
90 unrelated .0298 .0103 .0078 .0073 .0076 .0075 .0072 .0081 .0106 .0272 
30 trios .0175 .0036 .0035 .0035 .0035 .0035 .0036 .0038 .0044 .0102 
8X 
          60 unrelated .0090 .0028 .0024 .0023 .0022 .0021 .0023 .0024 .0031 .0072 
90 unrelated .0072 .0018 .0014 .0016 .0016 .0016 .0016 .0017 .0020 .0058 
30 trios .0035 .0008 .0007 .0008 .0008 .0008 .0008 .0008 .0009 .0026 
 
         In samples of trios and unrelated individuals at the sequencing depth of 1X, 2X, 4X, 8X and base error rate of 0.01
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Table 4.8 Comparisons of mismatch rate between the child and the parents for the simulation of 30 trios 
 
     
  All Sites  Heterozygous Sites 
Error Sample  1X 2X 4X 8X  1X 2X 4X 8X 
0.01 Parents  .0395 .0160 .0045 .0010  .0523 .0175 .0050 .0013 
 Child  .0348 .0134 .0030 .0003  .0524 .0173 .0045 .0008 
            
0.001 Parents  .0333 .0113 .0035 .0008  .0617 .0173 .0047 .0012 
 Child  .0293 .0093 .0022 .0002  .0587 .0161 .0043 .0008 
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Figure 4.1 Workflow of SNP discovery and genotype calling 
 
 
 
 
This figure describes a typical pipeline currently used in next generation sequencing studies. This 
paper focuses on the last step of refining genotypes and haplotype inference.  
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Figure 4.2 Cartoon view of LD-aware method for unrelated samples and parent-offspring trios 
 
 
 
 
This cartoon sketches our method. The top left panel is the unrelated reference haplotypes. The top right figure is the current updating trio. The bottom figure is 
one of the parents in the trio awaiting for updating.  In the trio, current configuration of the two haplotypes is shown next the each individual and the grey letters 
indicate uncertainty of the genotypes inferred from individual sequence data. 
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Figure 4.3 Frequency stratified mismatch rate at heterozygote sites at different depths for 30 trios, 60 unrelated and 90 
unrelated samples at base error rate 0.01 
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Figure 4.4  Genotype distributions and disconcordance for heterozygotes, reference homozygotes and alternative homozygotes 
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APPENDIX 
 
Sampling an Initial Haplotype Set 
To start the hidden Markov chain, I need to make an initial guess of genotypes and haplotypes. 
There are several ways to obtain the initial genotypes. I proposed two as follows. 
1. Single marker genotype call and random haplotype inference 
For each unrelated sample, the individual genotype is usually inferred by calculating the posterior 
probabilities P(G|R) = P(R|G)×P(G)/P(R) based on the estimated population frequency P(G). 
The genotype is unordered and no phase information is available from this initial guess.  For 
parent-offspring trios, the accuracy of the initial guess will be greatly improved by calculating 
posterior probabilities conditional on the whole trio. For example, 
  
More importantly, if I order the genotypes as mentioned above - that the allele of  
each parent always passes to the offspring - the initial inferred haplotypes are much closer to the 
true haplotypes than randomly filled haplotypes. The reason is similar to phasing trios with 
known genotypes, where uncertainty only occurs at sites that are heterozygous in all trio members. 
The initial inference of the haplotypes at highly covered sites facilitates the follow-up phasing 
procedure and improves the convergence of the algorithm. The benefit becomes even larger as 
sequencing depth of coverage increases.  
 
2. External genotypes and haplotypes from other software 
The alternative way to have an initial haplotype configuration is through other software (e.g. 
BEAGLE). It is usually better than random guess and can speed up our method by reducing 
iterations.  
), |()()()|()|()|(),,|(
,
mf
GG
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Chapter 5  
State Space Reduction Model for Haplotyping and Genotype Calling 
 
 
5.1 Introduction 
 
Genome-wide association studies (GWAS) have recently been a powerful method to 
discover the genetic basis of human disease in the area of human genetics.  GWAS try to 
identify causal single nucleotide polymorphisms (SNP) which contribute to complex 
disease. Most GWAS use commercial DNA chips to genotype typically hundreds of 
thousands of SNPs to serve as proxies of causal SNPs in the whole genome. A key 
problem of such studies is the imputation of missing genotypes and haplotype inference, 
which help detect additional signals and combine multiple data sets across multiple 
platforms. Hidden Markov model (HMM) is a commonly used tool to describe the special 
features of the sampled haplotypes [8, 11-13, 81]. This approach has been widely used in 
many GWAS and meta-analysis across multiple platforms [4, 86].  As the rapid 
development of next generation sequencing technologies, this model has been extended 
to deal with shotgun sequencing data. As the scale of the data increases, the 
computational challenge requires more attention. Table 5.1 describes the typical running 
time and memory requirement in haplotype inference using widely used software MaCH. 
When the number of samples reaches thousand, using all template haplotyes as state 
space becomes infeasible in practice. Motivated by the practical needs, I proposed a fast 
but mathematically and numerically equivalent algorithm to partially overcome the 
computational burden. I organize our paper as follows.  First, I describe the underlying 
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model used in haplotype inference and highlight the computational difficulty. Second, I 
propose a state space reduction algorithm to reduce the computational burden, but retain 
the same accuracy. Finally, I evaluate our method through both simulated and real data 
sets and compare the performance with standard methods.  
 
5.2 Method 
 
In this section, I will illustrate how the space state reduction method works efficiently in 
the framework of standard HMM approaches used in haplotype inference. This 
framework is consistent with Li et al. [14]. 
 
Describing Chromosomes as Imperfect Mosaics 
 
Hidden Markov models can be used to describe the haplotypes of each individual as 
imperfect mosaics of other haplotypes in the sample[81]. The approach is commonly 
used for genotype imputation [10, 12, 14] and can be extended to the analysis of short 
read sequence data [75]. In this section, I briefly review how these models can be used to 
model sequence data in unrelated individuals. First, haplotypes for each individual are 
initialized randomly – sampling a genotype consistent with observed read data at each 
position. Then, I iterate over individuals, updating the haplotypes of each individual 
using a hidden Markov model that describes the pair of haplotypes as an imperfect 
mosaic of other haplotypes in the sample. 
 
To describe the model, it is sufficient to specify how haplotypes for one individual can be 
updated conditional on current haplotype estimates for all other individuals. In the first 
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step, is to define P(Gi|Si), which is the probability of an underlying true genotype Gi 
given mosaic state Si. To calculate this, I use the function T(Si) which returns the number 
of variant alleles in the template haplotypes indexed by Si. Consistent with Yun et al [14], 
I define: 
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Then, the second ingredient in the definition of our hidden Markov model is to define the 
transition probabilities P(Si+1|Si). 
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Here, (x,y) and (w,v) denote indexes for the template haplotypes at position i and i+1. 
With all elements discussed above, I can calculate posterior probability P(Si|G), which 
can be used to infer genotypes for ith marker through function T(Si). Recall Si is the 
underlying pair of haplotypes, G is the all read information for current updating sample.  
This nontrivial calculation is proportional to P(G,Si), which can be simplified by Baum’s 
forward-backward algorithm through a recursive formula[83] as follows. 
Left probability for i+1th marker is denoted as Li+1 
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I start with equal probabilities for first marker and loop through all markers for possible 
pairs (w,v). At the Mth marker, I obtain the joint probability LM(w,v) = P(G,SM=(w,v)).  
The right probability Qi+1(w,v) function is defined as: 
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At the last variant site M, the function is defined as 1(w,v)=QM  for convenience.  
Finally, I have ),(),()),,(()|),(( vwQvwLGvwSPGvwSP iiii ×==∝= . 
Again, (x,y) and (w,v) denote indexes for the template haplotypes. 
I can obtain the posterior probabilities by a simple product of left and right probabilities 
at the same position. The genotype calls can be inferred from the probabilities 
conveniently.  
              
),(),()),,(()|),(( vwQvwLGvwSPGvwSP iiii ×==∝=  
Another asymptotically equivalent approach is through a sampling procedure. For each 
updating sample, I sample states from the Mth marker from LM = P(G1,G2,…,GM, SM). 
Then I continue to sample haplotypes reversely from Li+1= P(G1,G2,…Gi, Si|Si+1), where 
Si+1 is the sampled states at i+1 th marker.  I summarize all sampled states after pre-
defined rounds for each sample.  
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The initial inference of the haplotypes can be randomly assigned or obtained from 
external software (e.g. BEAGLE[11]), which has been described in the last chapter 
appendix.  
 
For each round, I can update the haplotypes for each sample and a pair of sampled 
haplotypes is stored for each sequenced individual. After a pre-defined number of rounds 
(e.g. M) are finished, a set of consensus haplotypes for each individual is generated from 
M sampled haplotype pairs. More specifically, for each individual, I need to specify a 
reference haplotype for each unordered haplotype pair by checking the first heterozygous 
site. Then, I can find the most frequent haplotype configuration for each subsequent SNP 
until a heterozygous state occurs. I flip the reference haplotype of the pair where the 
configuration is the other heterozygous state. I repeat this procedure until the last marker. 
 
State Space Reduction Method 
The key step of the calculation described above is the recursive formula in forward 
calculation. This calculation requires looping from first to last maker (M markers). At 
each marker, I need to calculate the probabilities L(x,y) for all possible states and store 
them for future use, which requires N2 memory space in the unit of float or double 
allocation. Therefore, the computational time and the memory cost are approximately 
proportional to MN2. The computational cost increases quadratically as the number of 
samples increases for each updating step. In the recent studies, a typical used reference 
panel is about 120 haplotypes for CEU samples from HapMap 2. However, the number 
will increase quickly to thousands in next two years when the 1000 Genomes Projects  
(www.1000genomes.org) and other large sequence projects are completed. The quadratic 
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increase of computational cost will make current algorithm impractical. Motivated by this 
practical challenge, I propose a state space reduction method to speed up the calculation 
and preserve the high accuracy of the HMM. The main idea is to take advantage of 
similarity among segments of chromosomes in short region and reduces the number of 
states in the forward calculation. The idea is inspired by the fact that the number of 
unique haplotypes increases slowly in a short region of the genome as the number of 
haplotypes increases, given the nature of inheritance according to coalescent theory. 
Typically, for current density of the reference panel, H different reference haplotypes can 
share a few identical short fragments in a narrow window, which is due to the tight 
linkage within a short region (Figure 5.2). I can illustrate this observation through a pool 
of 10,000 simulated chromosomes. The simulation details will be given in the simulation 
section. In Figure 5.2(a) and (b), a 10kb window is randomly chosen and I counted the 
average unique haplotypes and the number of the SNPs as the number of individual 
increases. In Figure 5.2(c), I plotted the number of unique haplotypes against the number 
of SNPs in the haplotypes in all 10,000 samples.   
 
Based on this process, I can segment the chromosomes into a series of short windows and 
reduce the number of reference haplotypes in each window, resulting in potential 
calculation savings. Figure 5.3 illustrates the idea. Assume that there are N template 
haplotypes with M markers. I divide the chromosomes into T windows and denote ti as 
the number of markers and hi as the number of unique haplotypes in the ith window. The 
strategy to allocate the windows will be discussed in next section. I summarize the 
algorithm in forward calculation within one window below: 
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1. At the start SNP of the window, calculate and store the full probability L(x,y) for each 
state.  
2. Within each window, fold the full probability into groups defined by the identical 
haplotypes segments in the window.  
3. At the last SNP of the window, unfold the group probability into full probability. 
4. Repeat 1-3 for all windows.  
 
This strategy reduces the state space with N2 to a reduced space of size N*hi within each 
window, hence it saves memory cost for storage of full probability and also reduces the 
computational cost.  
 
I describe the details in step 2 and 3. The main idea is illustrated in Figure 5.3. Assume 
the current window is from pth to qth marker and the full probability at pth marker is 
Lp(x,y), where x or y is from 1 to N, indicating each reference haplotype (Figure 5.3(a)). 
The standard forward calculation requires us to calculate N2 probabilities pth marker and 
continue to qth marker regardless of the haplotype configuration within the window 
(Figure 5.2(b)). Let the number of unique haplotypes within this window be h. Denote x* 
as the group xth haplotype belongs to, so the x* ranges from 1 to h and x ranges from1 to 
N.  Then, I define four types of quantities in a reduced space at each marker in the 
window. Within the window, LiNR(x*,y*), Li1RL(x*,y), Li1RR(x,y*) and Li2R(x*,y*) are the 
grouped probabilities with no recombination at both chromosomes, recombination only in 
first chromosome, recombination only in second chromosome and recombination in both 
chromosomes between first and ith marker respectively.  
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First, I initialize the four quantities  
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Second, I calculate the four quantities along the window recursively 
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At the end of the window (qth marker), I can recover the full probability in full state 
space based on the four grouped quantities in reduced state space (Figure 5.3(c)).  
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I need to emphasize that the covered full space quantities Lq(x,y) is exactly same as the 
calculation from standard forward calculation in full state space. Hence, it is an exact 
method without any approximation to original HMM. I can move forward and loop 
through all windows. At each marker, only a set of grouped quantities are stored.  
 
Optimization of Window Allocation 
An inevitable question concerns the allocation of the windows. A very long window will 
yield many unique haplotypes while a very short window will yield many overhead costs 
on the boundaries of each window. An optimal strategy could be explored. Since the total 
computing cost is the sum of the calculation on the two boundaries of each window in 
full states and within the window in reduced states, an optimized window allocation 
based on the panel density will affect the final performance greatly. I am motivated by 
the dynamic programming for the shortest path problem.  To illustrate the idea, I first 
define some cost (memory or CPU) functions:  
C(i) : cost for ith marker in full space,  C(1,i) : total cost from first to ith marker,  
C(g(i,j)): cost to calculate from ith marker to jth marker in reduced space 
 
The goal is to find a path Path(1,M), which minimizes C(1,M), where M is the total 
number of markers.  Since the number of all possible paths increase exponentially with 
M, looping through all path space is infeasible.  Here, I present a dynamic programming 
strategy to find the optimal path. Assume there is an optimal path Path(1,i) minimizing 
the cost from first marker to ith marker C(1,i) for all i < k, the optimal path Path(1,k) is  
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min{ C(1,k) + C(g(k-1,k)), C(1,k-2) + C(g(k-2,k)), …, C(1,2) + C(g(2,k)) }. The 
computational complexity of looping from first marker to Mth markers with this dynamic 
programming is O(M2), which is trivial compared to the forward calculation O(N2M).  
Here N is the number of template haplotypes. 
 
 
Simulated Data 
 
I simulated a pool of 10,000 chromosomes in 1Mb region which mimics the degree of 
Linkage Disequilibrium (LD)  in CEU samples [84]. Then, a subset of 50, 100, 200, 400 
and 800 unphased individuals was randomly drawn from the reference pool.  Three sets 
of the markers with 200 SNPs each were included in our simulation, representing 
different density panels similar to practice: a) 1 SNP per 5kb; b) 1SNP per 1kb; c) 1 SNP 
per 200b. I repeated above simulations for 100 times.  
 
Real Dataset 
I applied our method to three published real data sets: 1) 2000 samples genotyped on 
500K chip from psoriasis GWAS; 2) 1094 samples from 1000 Genomes Project 
genotyped on Illumina Omni platform; 3) 1094 samples from 1000 Genomes Project 
Phase I data (www.1000genomes.org). The densities of the three data sets are 
approximately 1 SNP per 5000 bases, 1000 bases and 200 bases respectively. I randomly 
picked 50, 100, 200, 400 and 800 samples from the data sets with a 500-SNP window. 
Both the state space reduction method and the standard method were applied to infer the 
haplotypes. 
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5.3 Results and Discussion 
 
As I discussed about the motivation of our method, the number of unique haplotypes 
increases slowly as the number of reference panel increases or the number of SNPs 
increases. I examined on a large pool of simulated haplotypes. In Figure 5.2 (a), for a 
fixed 10kb window, the number of unique haplotypes from 40 to 120 as the number of 
individuals increases from 200 to 1500. In Figure 5.2(b), the number of SNPs increases 
from 60 to 120 as the number of individuals increase from 200 to 1500. In Figure 5.2 (c), 
for a fixed sample size (N = 10,000), the number of unique haplotypes increases from 40 
to 180 as the window size increases from 50 to 200. The pattern is consistent with the 
coalescent theory that the number of unique haplotypes increases in a log scale as the 
number of sequences increases, but increases linearly as the region expands [87].  
 
Next, I will show the performance of our method in terms of CPU time and memory, 
compared to standard HMM algorithm. Table 5.2 presents the comparisons of the 
standard approach and our state space reduction method on three sets of simulated data. 
The general conclusion is that our method can reduce savings substantially in memory 
and computing time. The actual savings vary on sample size and marker density.  The 
standard method performs consistently in different densities as expected and increases 
cubically as the sample size increases while our state space method increases more 
slowly. More specifically, for the density of 1 SNP per kb, the memory savings increase 
from 3 folds to 8 folds and the computing time savings increase from 2 folds to 6 folds as 
the sample size increases from 50 samples to 800 samples. The performance is better for 
the density of 1 SNP per 200b and slightly worse for the density of 1 SNP per 5 kb.  
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Despite the encouraging performance of our method in simulation data sets, real data sets 
are more useful to estimate the actual savings in practice. Table 5.3 presents the 
comparisons of computational cost in real data sets. The performance is similar to what I 
observed in simulated data sets. With 50 samples in the lowest density of 1 SNP per 5 kb, 
memory saving is about 3 fold and cpu time is comparable. With 800 samples in the 
highest density of 1 SNP per 200 b, memory saving is about 20 fold and CPU saving is 
about 6 fold.  
 
Given the consistent results for both simulated and real data sets, I can conclude that the 
proposed state space reduction method can have a substantial saving in memory cost and 
a modest saving in computing time, comparing to the standard method, especially with a 
large number of samples. As the state space expands and density of the reference panel 
increases, I expect to have more gains.  
 
From a pure algebraic point of view, the standard forward calculation in HMM here is 
just a series of matrix and vector operations. The calculation will go through each 
element of the matrix ignoring the specific properties of the matrix pattern. The state 
space reduction method is reorganizing the probabilities into a group of vectors with 
same properties and performing the calculation in a condensed way. Despite of the 
numerically equivalence of the calculation, the mathematical proof for haploid case is 
provided in the supplemental materials. The diploid case is very similar.  This idea is 
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potentially useful in more general scenarios where the transition and emission probability 
matrices are in specific formats. 
  
Accuracy is not shown here because our method is numerical equivalent to the standard 
HMM implemented in MaCH. The accuracy of MaCH and other software has been 
comprehensively discussed [8, 88]. MaCH implemented the standard HMM efficiently 
using symmetric matrix for probabilities storage. The actual computing time and memory 
are halved compared to the standard approach in Table 5.2 and Table 5.3. Our method 
still outperforms MaCH in both computing time and memory, which suggests a potential 
replacement of MaCH for the purpose of haplotype inference for future application.     
 
This algorithm can be potentially incorporated into some existing program such as MaCH 
[14]. A separate pre-released version for haplotype inference can be requested 
individually from the author at weich@umich.edu .  
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Table 5.1  Estimate of running time and memory for haplotype inference using 
MaCH 
 
          
Sample 100 500 1000 2000 
Time (hours) 0.47 59 472 3778 
Memory (Gb) 0.08 1.99 7.98 31.97 
      
The estimate is based on a single 2.8 GHz AMD Opterons CPU. For each data set, all 
samples are used to perform a full state space calculation. The number of iterations is set 
to 50.  
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Table 5.2  Comparisons of the computing time and memory in simulations 
              
  Samples 50 100 200 400 800 
5Kbp 
      Memory(M) Standard 7.7 31.5 127.4 512.0 2,053.1 
 
Grouping 2.9 9.2 29.3 93.9 316.3 
       CPU(s) Standard 28 226 1,796 15,014 124,448 
 
Grouping 18 113 827 7,393 63,696 
       1Kbp 
      Memory(M) Standard 7.7 31.5 127.4 512.0 2053.1 
 
Grouping 2.3 7.3 24.0 79.2 269.4 
       CPU(s) Standard 27 222 1,813 15,542 132,422 
 
Grouping 14.2 83.8 519.7 3,622 28,148.7 
       200bp 
      Memory(M) Standard 7.7 31.5 127.4 512.0 2,053.1 
 
Grouping 1.6 5.0 16.1 53.5 179.0 
       CPU(s) Standard 28 222 1,785 15,313 124,895 
  Grouping 11 59 345 2,233 15,937.6 
       Comparisons of the computing time and memory between standard approach and state space reduction 
method for simulated data sets with 200-SNP window in three different densities (1 SNP per 
5Kb/1Kb/200b) 
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Table 5.3  Comparisons of the computing time and memory in real data 
              
  samples 50 100 200 400 800 
GAIN_500K 
      Memory(M) Standard 19.2 78.4 316.8 1,273.6 5,107.2 
 
Grouping 6.2 18.6 58.1 188.5 629.4 
       CPU(s) Standard 72 590 4,931 42,733 354,089 
 
Grouping 49 346 2,642 20,361 156,212 
       1KG_OMNI 
      Memory(M) Standard 19.2 78.4 316.8 1,273.6 5,107.2 
 
Grouping 3.7 11.0 33.7 127.1 464.0 
       CPU(s) Standard 71 576 4965 42,342 353,343 
 
Grouping 38.2 256.4 1947 15,111.4 115,713.9 
       1KG 
      Memory(M) Standard 19.2 78.4 316.8 1,273.6 5107.2 
 
Grouping 2.7 8.3 26.9 100.4 361.4 
       CPU(s) Standard 72 577 4,851 42,882 354,920 
  Grouping 22 121 756 5664 46,285.8 
       Comparisons of the computing time and memory between standard approach and state space reduction 
method for real data with 500-SNP window 
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Figure 5.1 Cartoon view of the standard hidden Markov model for imputation and 
haplotype inference 
 
 
 
 
Haplotype inference of current updating sample. (a) A number of samples with observed genotypes. The 
bottom sample is being updated. The rest of the samples are treated as template haplotypes with random 
haplotypes assigned initially. (b) The phasing haplotypes of current sample are identified by mosaics of 
short stretches of the template haplotypes. 
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Figure 5.2  The pattern of the number of unique haplotypes (for a fixed window of 
10kb) 
 
 
 
(a) The increasing pattern of unique haplotypes as the number of individuals increases. 
(b) The increasing pattern of SNPs as the number of individuals increases. 
(c) The increasing pattern of unique haplotypes as the number of individuals increases based on a pool of 
50,000 samples 
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Figure 5.3  Decomposition of template haplotypes 
 
 
 
This example consists of 200 haplotypes with 100 SNPs. 100 SNPs were chunked into difference windows. 
Within each window, the number of unique haplotypes is counted. E.g. The first windows consists of 10 
SNPs and 20 unique haplotypes.  
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Figure 5.4  Cartoon view of the state space reduction method in an exampled 
window 
 
 
 
 
 
 
(a) Grouping of unique haplotypes in colored window. Color indicates the different groups in the window. 
(b) The standard forward calculation from pth marker to qth marker.  
(c) The state space reduction method from pth marker to qth marker 
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Supplemental Materials 
 
Proof of the equivalence in probability of the two approaches for haploid case 
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 101 
 
 
Chapter 6  
Summary and Discussion 
 
 
So far, I have shown several topics I have been working on in the past few years. These 
novel methods and analysis results are all motivated from the experimental genetic data 
and have practical importance.  I will briefly summarize each chapter and then discuss 
about their limitations and possible future work. Furthermore, I will also discussion 
ongoing work will also be discussed.  
 
6.1 Summary and Future Work of Chapter 2-5 
 
In Chapter 2, I presented a genome-wide association study on AMD and proposed a  
prediction model to investigate the cumulative risk of individuals. A novel gene TIMP3 
was identified and a potential interesting HDL-related pathway was proposed to be 
associated the AMD. Those findings broaden our knowledge of etiology of the disease 
and improve our understanding of biology in the retina. In addition, integrating all known 
and novel loci, a prediction model based on logistic regression can cluster high and low 
risk patients very well and will potentially be useful in clinical practice.  
 
In Chapter 3, motivated by the numerous requests for GWAS results from collaborators, I 
developed an efficient user-friendly program to store and visualize the results, especially 
for multiple dimensional phenotypes. A successful application example is used in a 
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project of expression Quantitative Traits Loci (eQTL). It has been downloaded over four 
hundred times.  
 
In Chapter 4, I proposed a novel method to infer genotypes and phasing for sequencing 
parent-offspring trios. This method was motivated by the ongoing Sardinia low pass 
whole-genome sequencing project. I combined the family constraints of parent-offspring 
trios and LD information into a unified framework. The results from simulation and real 
data sets suggest that my method can improve the genotype accuracy significantly. In 
addition, the haplotype inference is also more accurate, which is often very crucial in 
follow-up imputation in existing GWAS data.   
 
In Chapter 5, I proposed a state space reduction method to reduce the computational 
complexity of existing programs for haplotype inference and imputation. The idea is to 
group the haplotypes, which have the same local sequences, into a reduced space and 
reduce computation and storage. With the same accuracy, this method can reduce the 
computational cost in both memory and CPU time greatly in the process of the forward 
calculation in the hidden Markov model. The gain is growing as the sample size 
increases.  
 
Although a lot of progresses have been done, none of the above topics reach the end. 
Those works have potential applications in the new context. I will brief describe some 
ongoing and future works.  
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Our GWAS in Chapter 2 identified a novel gene and a potentially interesting pathway. To 
detect more genetic variants with small effect size or low minor allele frequency, more 
samples are needed. A common approach is meta-analysis: combining a number of 
studies with GWAS data and estimating pooled pvalue. To achieve this goal, an 
international consortium “AMDGene Consortium” was organized with over 15 groups 
with a total of ~8000 cases and ~50,000 controls. As one of the core members, my work 
involves designing the analysis protocol, checking data quality and conducting the 
analysis. I applied both z-statistic and inverse variance method to the data [89]. The 
preliminary results are very promising and confirmed my findings in Chapter 2 and also 
brought the two proposed interesting hits to the genome-wide significance. Besides that, 
several new signals have been identified and under replication in several independent 
studies with a total of ~10,000 cases and ~8,000 controls. All those findings will greatly 
improve our knowledge of genetic basis of AMD and provide more clues about biology 
of the disease. As sequencing cost drops, sequencing in known genes, exome and whole 
genome will become feasible. This will further our understanding of AMD and biology of 
retina.  
 
With the rapid advances of the next generation sequencing technology, I will have more 
computational and statistical challenges with huge amount of sequencing data. The 
method I have developed for SNP calling and haplotype inference for parent-offspring 
trios will have more applications in the real data analysis. However, as I can expect the 
sequencing cost will reduce drastically in the next several years, more family-based 
sequencing projects will be carried out. My method could be extended to nuclear and 
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general family in a few ways, from heuristic to more complicated approaches. I will 
explore more in this direction to assistant existing and future sequencing projects. With 
this tool in hand, together with the variant calling method my colleague Bingshan and I 
developed, I plan to study the optimal design at different scenarios. For example, people 
would like to know if sequencing 100 parent-offspring trios at the coverage of 8X has 
more power to detect association signals than sequencing 100 nuclear families with two 
children at the coverage of 6X given the same sequencing cost.  
 
6.2 Ongoing Work and Future plan 
The next crucial step after genotype calling is association test. The fast increasing number 
of variants poses the difficulty in multiple testing problems. I would like to briefly 
describe an ongoing work to control the false discovery rate (FDR) accounting for 
correlations, which is potentially useful in genetic association studies. Methods of FDR 
control are widely used in genetics and genomics study [90]. However, the traditional 
procedures usually ignore the dependency of the tests, resulting loss of power. Genome-
wide association study (GWAS) examines the association between phenotype and 
hundreds of thousands SNPs. The highly correlated structure of the SNP array requires 
some novel method to account for the dependency information.   
 
It is motivated by the paper Sun and Cai (2007), which shows z statistic based method is 
more powerful than p-value based methods. In particular, their procedure is very useful 
when the underlying dependence structure forms a markov chain with time-independent 
transition matrix [91, 92].  However, the assumption of constant transition matrix does 
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not hold in practice and may result in loss of efficiency. I aim to extend their approach 
under more general dependence structure, (e.g. time-dependent transition matrix) and 
incorporate some prior information from raw data to increase the power while controlling 
the nominal FDR level. First, I present a HMM approach described in Sun’s paper.  
 
Assume there are m tests, with observed a test statistic xi   i = 1,2,…,m in some specific 
order. The hidden state is denoted as  θi = 0 (null) or 1 (signal). The transition matrix 
between adjacent tests is defined as  𝐴𝐴 =  � 𝑎𝑎 1 − 𝑎𝑎1 − 𝑏𝑏 𝑏𝑏 �.  
Emission probability is defined as xi | θi = 0 ~ N(0,1),   xi | θi = 1 ~ N(µ,1) (or mixture  
normal).  Local index of significance (LIS) is defined as    𝐿𝐿𝐿𝐿𝐿𝐿𝑖𝑖 = 𝑃𝑃𝜗𝜗(𝜃𝜃𝑖𝑖 = 0 |?⃗?𝑥), where  
𝑃𝑃𝜗𝜗(𝜃𝜃𝑖𝑖 = 0 |?⃗?𝑥)  is the posterior probability calculated by forward backward algorithm. 
𝐿𝐿𝐿𝐿𝐿𝐿 𝑘𝑘 = max �𝑖𝑖: 1
𝑖𝑖
∑ 𝐿𝐿𝐿𝐿𝐿𝐿�𝑖𝑖𝑗𝑗=1 (𝑗𝑗 ) (𝑥𝑥) ≤ 𝛼𝛼�,   rejecting all  𝐻𝐻(𝑖𝑖), 𝑖𝑖 = 1, … ,𝑘𝑘  , controls FDR 
level at 𝛼𝛼.  
 
As a demonstration example, I assume initial state distribution 𝜋𝜋 = (1,0), Transition  
matrix    𝐴𝐴𝑖𝑖 =  � 0.8 0.21 − 𝑎𝑎𝑖𝑖 𝑎𝑎𝑖𝑖 �  
Underlying state θi = 0 or 1.  0 refers non-significant, 1 refers significant.  
The observations 𝑥𝑥𝑖𝑖  , i = 1,2,…,m are generated by following distribution: 
 xi | θi = 0 ~ N(0,1),   xi | θi = 1 ~ N(µ,1)  
I applied conventional method BH procedure, adaptive p-value procedure, homogeneous 
HMM approach (OR) and nonhomogeneous HMM (OR.1) approach to the data and 
compare FDR and FNR.  
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For nonhomogenous transition matrix, the parameters are difficult to estimate and often  
not identifiable. If the transition matrices share the same set of parameters, I can estimate 
them through an EM algorithm. Although there is no theory to guarantee the 
convergence, it converges for most cases in practice from our experience.  
                         
In the demonstration example, the simulation results (Figure 6.1) show that BH is always  
conservative as expected, while the other three procedures control FDR at desired level 
even for non-homogenous case. OR.1 has more power (less FNR) than other three since it 
considers the true nonhomogeneous matrix especially in modest size of signals.  
However, in reality, it is difficult to estimate all parameters with the assumption that each 
transition matrix has its own parameters.  Instead, I can assume some pattern of the 
transition matrices such that they share same set of parameters.  
 
GWAS examine tens of thousands SNPs placed along the genome. SNPs tend to be 
correlated with each other in short region due to linkage disequilibrium, often measured 
in r2. Figure 6.2 shows the distribution of r2 on chromosome 22 from HapMap project. 
LD between SNPs can extend as far as a few hundred thousand bases, which results to 
clusters of signals.  In next generation sequencing, multiple rare variants not easily 
tagged by common SNPs in small region may cause similar patterns.  I aim to propose 
some realistic transition matrices to account for LD information between adjacent SNPs 
and increase the power to detect true variants.   
 
A simple starting example is defined below: 
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𝐴𝐴𝑖𝑖 = �𝑝𝑝0 + 𝑟𝑟𝑖𝑖2(1 − 𝑝𝑝0) (1 − 𝑝𝑝0)(1 − 𝑟𝑟𝑖𝑖2)𝑝𝑝0(1 − 𝑟𝑟𝑖𝑖2) 1 − 𝑝𝑝0 + 𝑝𝑝0𝑟𝑟𝑖𝑖2 � 
 
where Ai and ri are the transition matrix and correlation for two adjacent SNPs. P0 is the 
proportion of false signals and requires be to estimated. Given this specific transition 
matrix, the E-M algorithm described previously can be used to estimate po. The p-value 
for each marker can be calculated through this process. I will explore it further in near 
future.  
 
6.3 Conclusion 
 
The research of human genetics will reach to another era with the breaking-through and 
remarkable technologies. The GWAS approach has proven to be successful to identify 
common variants associated with various disorders or complex traits. Next generation 
sequencing provides a deep catalog of the human genetic variations and enables us to 
look for missing heritability through rare variants and mutations. However, we are still 
far away from the ultimate goal: the cure of human disease. The intermediate steps 
require many novel statistical and computational methods to deal with prodigious 
accounts of data from different levels: DNA, RNA and protein. Careful analysis and 
appropriate interpretation will help us to understand the fundamental mechanisms of the 
biology.  I believe what I have done and what I plan to do will continue to facilitate the 
discovery of diseases-associated genes/pathways and understanding of the etiology of the 
disease, particularly in the context of large-scale sequencing.  
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Figure 6.1 A comparison of some conventional methods, homogeneous HMM 
approach and non-homogeneous HMM approach 
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Figure 6.2 Raw R2 distribution from chromosome 22 
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